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Abstract  
Background 
Cognitive impairment is common even in newly diagnosed Parkinson’s disease (PD), 
and characteristically involves executive and visuospatial functions with deficits also 
in the memory domain. There is an increased risk of dementia associated with the 
diagnosis of PD, with an almost sixfold increased risk of becoming demented 
compared with subjects without PD.  
The morphologic changes of grey and white matter which accompany cognitive 
impairment in early PD, and  dementia in PD are incompletely understood.  
The first study to compare whole brain atrophy in PD versus other types of dementia 
was published in 2004, showing that the pattern of grey matter loss in PD and PDD 
was different from the changes found in AD. Occipital atrophy was found in the PDD 
group and frontal volume loss in PD without dementia. No difference in grey matter 
volume was found between PDD and DLB patients. The studies that have been 
published since, have in part confirmed these results, but also conflicting results have 
been found. No studies have previously looked at white matter hyperintense lesions 
in MR images of PD patients and their impact on dementia in PD. 
Hypotheses 
The frequency and extent of white matter T2 hyperintense lesions (WMH) are 
associated with dementia in PD.  
The pattern of grey matter atrophy in PD is different from atrophy in normal ageing, 
patients with PDD and PD with mild cognitive impairment. 
Grey matter atrophy in patients with PDD differs from the pattern of atrophy in 
patients with Alzheimer’s disease but not from patients with Dementia with Lewy 
Bodies. 
Patients with PD who develop dementia early in the disease diagnosis have more grey 
matter atrophy than patients who develop dementia late in the disease course. 
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Subjects 
Patients were recruited by doctors in the outpatient clinics of the Department of 
Neurology, Department of Geriatric Medicine and the Department of Old Age 
Psychiatry at Stavanger University Hospital in the period from 2001 to 2005. One 
group was recruited from an ongoing longitudinal study, the Parkinson-study of 
Rogaland, during their annual follow up (n= 17). Another group consisted of 
consecutive patients with PD with and without dementia. Patients with Alzheimer’s 
disease and DLB were also recruited. Healthy elderly volunteers were recruited from 
Stavanger and the surrounding district. 
 
Methods 
After a clinical assessment including evaluation of cognition, motor symptoms and 
psychiatric symtoms patients were diagnosed according to established diagnostic 
criteria for PD and dementia. Healthy controls completed a brief interview and a mini 
mental state evaluation (MMSE). All patients and controls completed an MRI 
examination with the same imaging protocol, in the same MRI machine. 
Images were analysed for white matter hyperintense lesions (WMH) using a semi-
quantitative visual rating scale. Unbiased whole brain image analysis with voxel 
based morphometry (VBM) was used for the evaluation of grey matter differences 
between groups. 
Results 
We found that white matter hyperintense lesions in T2 weighted series on MRI are 
not increased in number or extent in the total PD group, but they were increased in in 
PDD compared to non-demented PD subjects.  
We found atrophy in PDD both in cortical and sub cortical grey matter compared to 
healthy subjects and non-demented subjects with PD. A novel finding was atrophy in 
grey matter observed in patients with MCI and PD compared to subjects with PD and 
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intact cognition, indicating that even the early cognitive changes in PD are associated 
with morphological brain changes.  
 The overall pattern of grey matter changes in PDD differed from that in AD and 
DLB, although overlapping regions of atrophy exists. In our study, DLB patients had 
more atrophy in parietal and occipital areas compared with PDD patients. 
We found that patients with PD who developed dementia early  had a different 
pattern of atrophy than those who developed dementia late in the course.  
 
Conclusion 
We found that there is no increase in WMH in PD compared to controls. The more 
severe changes found in PDD however, suggests that in some patients WMH may 
contribute to cognitive impairment.  
Our grey matter findings are in line with other studies, supporting the hypothesis that 
morphological changes in the cortex contribute to dementia in PD. We found grey 
matter structural changes associated with cognitive impairment in PD, thus cognitive 
impairment early in PD are not entirely based on functional changes. Differences 
found between DLB and PDD shed light on the ongoing discussion whether DLB and 
PDD are different diseases or represent stages on a continuum of Lewy body disease. 
The results of the studies included in this thesis, gives valuable new information 
about structural changes accompanying PD both in white matter and grey matter, and 
our results give rise to new hypotheses for future imaging studies of PD. Challenges 
for future studies  will be to find which brain changes that reliably can predict 
development of dementia in PD.  
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1. Introduction 
1.1 Magnetic Resonance Imaging (MRI) 
1.1.1 History of MRI 
The physical phenomenon of nuclear magnetic resonance (NMR) was first 
discovered by Isidor I Rabi in 1938.1 He was awarded the 1944 Nobel Prize in 
Physics for his method for recording the magnetic properties of atomic nuclei. 
(http://nobelprize.org) Felix Bloch and Edward Purcell are considered to be the 
inventors of magnetic resonance imaging (MRI), for which they were awarded the 
Nobel Prize in Physics in 1952. (http://nobelprize.org) It was not until the 1970s the 
principle of nuclear magnetic resonance could be used to make images of the body. In 
1973, Paul Lauterbur, a chemist at the State University of New York, Stony Brook, 
produced the first NMR image.2 Peter Mansfield, a physicist working in Nottingham, 
England, further developed the utilisation of gradients in the magnetic field. 
Mansfield’s work showed how fast MR imaging could be achieved.3 In 2003 
Mansfield and Lauterbur were awarded the Nobel Prize in Medicine for their 
pioneering contributions, which later led to the application of magnetic resonance in 
medical imaging.  
1.1.2 Principles of MRI 
In MRI the magnetic properties of the hydrogen nuclei of the body are utilised. 
Hydrogen nuclei contain only one proton, and are therefore often referred to as 
protons. All MRI used in clinical medicine utilise the NMR from the hydrogen 
nucleus. Hydrogen nuclei give the best NMR signals, and are the most common 
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atomic nuclei in the body.4 Similar to a bar magnet, the hydrogen nucleus has a 
magnetic moment and an associated magnetic field. In the natural state these 
magnetic dipoles are randomly oriented. When the protons are placed in a powerful 
magnetic field, as in a MRI machine, these little dipoles align with the external 
magnetic field. They either align parallel or anti parallel with the direction of the 
magnetic field. There is an overweight of protons that align parallel to the magnetic 
field, but only as little as 1 proton per million. This results in a net magnetic moment 
parallel to the magnetic field, created by the sum of the individual protons’ magnetic 
moments. The protons that are aligned parallel to the external magnetic field have 
lower energy than the anti-parallel protons.5 When they are exposed to a signal of 
electromagnetic radiation, they generate a signal, the NMR. The NMR that is the 
basis for creating images are thus signals generated in the body and detected in an 
antenna /coil which is placed around the protons, i.e. the patient. 
 The electromagnetic radiation that can produce NMR must have the same frequency 
as the spin of the atomic nucleus, the resonance frequency (RF). In clinical MRI the 
RF is usually in the so called radio-frequency area. RF stimulation causes the nuclei 
to absorb energy, and lifts them to an excited state. In order to return to the lower 
energy state the excess energy of the nuclei is released to the surrounding tissue.5 
Following RF pulsing, the strength and origin of the magnetic signals can be 
determined by magnetic field gradients that are superimposed on the magnetic field in 
the MR machine. This spatial information can be encoded electronically and 
reconstructed into a cross-sectional image.6 Each cross sectional MR image is based 
on a matrix of numbers, each assigned a shade of grey. The numerical value of each 
voxel (i.e. picture elements in three dimensions) in the image represents the intensity 
of the NMR emanating from the tissue following a RF pulse. Depending on the RF 
pulse(s) and the sampling time of the signal, different contrasts between tissue classes 
can be depicted.7 Image contrast is created by using a selection of image acquisition 
parameters that weights signal by e.g. T1, T2 or no relaxation time ("proton-density 
images"). MR images have good tissue contrast which means the ability of 
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differentiation between tissue types is good. There is also good differentiation 
between normal and pathologic tissue.  
T1 contrast 
After an RF pulse stimulation, the protons are “excited” for a short time, but the 
added energy diminishes and after a while the protons have regained their original 
(lower) energy level. This process depends on the protons’ ability to align with the 
external magnetic field, which differs for different tissue types. For example in lipids 
protons will relax faster than protons in water,  or in molecules that are much larger.5 
In the time period of returning to lower energy state, the NMR signal will gradually 
decay and disappear. The T1 relaxation time is the time it takes for 63% of the 
protons to align with the external field of magnetisation. A sampling of the NMR 
signals in a T1 relaxation gives T1 weighted images. T1 time is tissue class 
dependent, and one of the reasons why MR images have good tissue contrast. In the 
brain, T1-weighting causes the nerve connections of white matter to appear white, 
and the congregations of neurons of grey matter to appear grey, while cerebrospinal 
fluid appears dark.4, 5 
 T2 contrast 
The T2 weighted images are obtained after a refocusing of the spins in the x-y 
direction following a 180 º RF pulse. T2 relaxation is caused by reduction in 
magnetisation in the X -Y plane, also called transverse relaxation. This is caused by 
in-homogeneity of the magnetic field on a molecular level, leading to a dephasing of 
the protons with decay of the transverse magnetisation. T2 relaxation time describes 
how fast the decay of the NMR is because of T2 relaxation. T2 time is longer in pure 
water than tissues or liquids containing protein.5 The contrast of "white matter," "grey 
matter'" and "cerebrospinal fluid" is reversed using T2 imaging compared to T1 
imaging. See figure 1, below. 
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Figure 1. Relative brightness levels for different material in T1 and T2 weighted scans. 
Courtesy of C. Rorden, Associate professor, University of South Carolina.  
 
Volumetric MRI  
The ability to acquire high-resolution three-dimensional (3D) imaging in MRI is the 
result of technical improvements and rapid scan techniques. Low flip angle gradient-
echo imaging is one method to do this, which I will not describe in detail. Through 
this method thin slices can be obtained, with voxel-size of 1x1x1millimeters. An 
advantage of 3D MRI is the ability to get detailed images of complex anatomical 
structures, like the brain. 
1.1.3 Structural Imaging 
Computer tomography (CT) and MRI are two methods for obtaining images of the 
structure of the brain. CT uses ionising radiation (x rays) that are potentially harmful 
for the patient, while no unwanted side-effects of MRI are so far discovered. 
Other advantages with MR images are that different sequences that can be applied in 
MRI reveals information about properties of the tissue being imaged. The 
discrimination between grey and white matter can be excellent e.g. in T1 weighted 
images, and this enables us to perform studies where different tissue classes can be 
segmented and treated separately. A combination of good T1 contrast between grey 
and white matter and a volumetric MR uptake of the brain gives us the opportunity to 
study structural differences between patients or groups of patients that are not 
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obvious by visual inspection. This can be done using a region of interest (ROI) 
approach where the investigators, based on a hypothesis, make measurements in 
specific areas of the brain. Another approach is the unbiased methods in which a 
data-based analysis is performed. This kind of analyses can be used both to test 
certain hypotheses, but they can also be performed without a pre-specified hypothesis 
and point the attention of the investigators to structural differences that have not 
previously been found. There are a number of different software available to perform 
such analyses e.g. Statistical parametric mapping (SPM) 
(http://www.fil.ion.ucl.ac.uk/spm), Freesurfer8, Brainvoyager 
(http://www.brainvoyager.com/) and Analyze (http://www.mayo.edu/bir/). The 
choice of method is guided by the hypotheses of the study, but also the availability 
and cost of using the different methods will influence the choice of method. The 
quality of the images will also decide which programmes can be used for image 
analysis. 
Disadvantages of MRI especially for studies of elderly and demented patients, or 
patients with movement disorders, are the movement artefacts produced when the 
patient is unable to lie still in the machine. This in combination with the prolonged 
scanning time for MR imaging may lead to acquisition of useless data. The noise in 
the scanner can be a problem as well, in addition to the limited space that may lead to 
a feeling of claustrophobia. Because of this and the unfamiliar setting for the patient, 
some dementia patients get agitated and cannot complete the imaging. Imaging with 
modern CT scanners now only take seconds to complete a scanning of the brain, 
while a typical MRI will take at least 15 minutes. Despite these disadvantages MRI is 
the method of choice for most structural imaging studies of the brain for research 
purposes. 
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1.1.4 MRI findings in normal ageing of the brain 
Grey matter 
Global thinning of the cerebral cortex has been found to start by middle age (third 
decade of life), and age-associated patterns of atrophy have been identified.9 
Prominent atrophy of the prefrontal cortex with relative sparing of temporal and 
parahippocampal cortex has been found in independent studies of normal ageing.9-11 
The preservation of temporal and parahippocampal structures is consistent with the 
functional importance of the thalamo-limbic circuits in sensory integration, arousal, 
emotion, and memory. Later-maturing cortical regions are thought to be more 
vulnerable to age-related morphologic changes.11 Atrophy of subcortical structures 
like the striatum has also been shown in healthy adults.12 Local areas of accelerated 
loss in normal ageing are also found bilaterally in the insula, superior parietal gyri, 
central sulci, and cingulate sulci.10 Conflicting findings exist regarding the interaction 
of age with sex for grey matter atrophy. One study found no regionally specific 
effects,10 while another group found greater cortical thickness in some regions in 
females relative to males independent of differences in brain or body size.13 
In a longitudinal study, decreases in cross-sectional whole-brain , temporal lobe , and 
hippocampal volumes and increase in ventricular volume is found with increasing 
age, with the most marked changes occurring after 70 years of age. The increase after 
70 years of age is found to be particularly marked in the ventricles and the 
hippocampi.14 Longitudinal change in atrophy of normal ageing often comes from 
studies where elderly are used as healthy controls, and reported annual percentage 
loss ranges from 0.215 to 0.4-0.5 %.16 
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White matter 
The structural integrity of myelin sheaths deteriorates during normal ageing, 
especially in the late-myelinating association regions and may result in 
"disconnection" of widely distributed neural networks.17 Age-related decline in 
frontal white matter (WM), the posterior limb of the internal capsule and the genu of 
the corpus callosum is found using diffusion tensor imaging.18 The same study 
showed that temporal and posterior WM was relatively preserved, suggesting that 
some fibre populations are more vulnerable to age-related degeneration than others.  
Deep white matter hyperintensities (WMH) are common on T2 weighted and fluid 
attenuated inversion recovery (FLAIR) images of elderly people. Gliosis, loss of 
myelin and loss of fibres are found in WMH histopathologically,19 and even in 
normal appearing white matter on MRI, damage associated with WMH is 
detectable.20 Combined MRI and pathology studies of WMH suggest that in vivo 
MRI is less sensitive than post mortem analyses to detect WMH,21 and propose that 
they originate from chronic hypoperfusion injury.22 
 
1.1.5 MRI in neurodegenerative diseases/dementia 
Alzheimer’s disease is the neurodegenerative disease that is most studied with 
neuroimaging methods. In the classical study by Jobst et al medial temporal lobe 
atrophy was found in CT scans of AD patients.23 This has later been confirmed in 
studies using MRI.24 Combined volumetric measures of the amygdala and septal area 
were found to distinguish patients with AD from normal control subjects with 93% 
accuracy.25 None of these methods are so far widely used for diagnosing AD in a 
clinical setting although it has been argued that it could be feasible.26 
 Asymptomatic persons from families with autosomal dominant AD had cortical grey 
matter loss in the preclinical stages in the medial temporal lobes, posterior cingulate 
and temporoparietal cortical areas.15 Volumetric analysis of the hippocampus and 
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entorhinal cortex showed that both persons with mild cognitive impairment (MCI) 
and early AD had volume reductions in these two areas,27 and in a VBM study grey 
matter loss has been demonstrated in persons with MCI that resemble those seen in 
early AD28This shows that there are available methods to detect preclinical stages of 
the disease, and therapeutic intervention can be applied if available. 
Neuroimaging investigations may be helpful in the diagnosis of dementia with Lewy 
bodies (DLB) the second most common neurodegenerative dementia.29 Significant 
differences between DLB and AD on MRI have been reported. The most typical 
finding is the preservation of the hippocampus and medial temporal lobe volume in 
DLB in comparison with AD.24, 30 These differences are based on group studies and 
cannot reliably differentiate between DLB and AD on an individual level, 
demonstrated by the rather low sensitivity (38%) reported31. Other changes, such as 
atrophy of the putamen32, basal forebrain33, 34, white-matter lesions35, and rates of 
progression of whole-brain atrophy36 are even less specific and not helpful in the 
diagnosis of individual patients. 
In a recent study involving the largest sample to date, using automated voxel-based 
technique without specifying an a-priori area of interest, a signal pattern involving 
focal atrophy of several areas, including substantia innominata, hypothalamus, and 
dorsal midbrain37 was found in DLB, indicating that this pattern of atrophy combined 
with a relative preservation of medial temporal lobes, is suggestive of DLB. 
However, these were group data and there is large degree of overlap between 
individuals in the AD and DLB groups. Sensitivity and specificity values were not 
reported. Thus, structural MRI cannot reliably distinguish between DLB and AD. 
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1.2 Parkinson’s disease (PD) 
1.2.1 PD without dementia 
Epidemiology 
Parkinson’s disease (PD) is a common neurodegenerative disorder of the elderly 
characterised by tremor, rigidity and slowness of movements. It was first described 
by James Parkinson in 1817 in his “An Essay on the Shaking Palsy”. The prevalence 
of PD is 100 to 150 patients per 100 000 inhabitants in Western Europe38-40 and 
USA41 and the prevalence increases with increasing age. Incidence rates for PD are 
shown to increase from 0.3 per 1000 person-years in subjects aged 55 to 65 years, to 
4.4 per 1000 person-years for those aged > or =85 years.42 The number of individuals 
with PD over age 50 in Western Europe's 5 most and the world's 10 most populous 
nations is expected to double reaching between 8.7 and 9.3 million by 2030.43  
Conflicting results have been published about the prevalence in developing countries 
compared to western countries. Some find PD to be less prevalent in the developing 
countries e.g. China44 and Bolivia45, while recent studies found no difference in the 
prevalence of idiopathic PD in Brazil46or China47 compared to western countries. 
Gender distribution is almost equal, although some have reported a slight male 
preponderance.48 
Etiology of PD 
The etiology of PD is not known but it is generally believed to be a multi-factorial 
disease process in which genetic, environmental, occupational and lifestyle factors 
individually and collectively play a significant role.49, 50  
There is considerable evidence suggesting that genetic factors can influence 
susceptibility to PD,51-53 especially in young onset PD. In late onset idiopathic PD 
however, the influence of genetics is found to be low, ~2 % for the LRRK2 gene51 
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Numerous environmental conditions are found to influence the risk of developing 
PD, and interaction between genetic polymorphisms and these environmental factors 
may be important for the development of idiopathic PD.54  
Midlife adiposity,55 infrequent bowel movements ,56 and postmenopausal estrogen 
use57 have been found to be associated with increased risk of PD. Childhood well 
water drinking ,58 exposure to certain pesticides,59, 60 and rural residence may also 
increase PD risk,61 but clear links between rural living and increased risk of PD has 
not been established.62 In contrast, smokers and coffee drinkers have a lower risk of 
PD63 although smoking does not seem to influence the course of disease.64 
Neuropathology of PD 
PD is characterised by loss and gliosis of the dopaminergic neurons of the substantia 
nigra pars compacta and the presence of intracellular inclusions called Lewy bodies 
(LB).65 Lewy neurites (LN), which are located in the axonal processes of neurons, 
indicate degenerating neurons present in PD patients.66 Poorly myelinated or 
unmyelinated projection neurons with long axons are predisposed to PD related 
pathology.67 Neuron loss and LB are not restricted to the SN, but are also found in the 
dorsal motor nucleus of vagus, nucleus basalis of Meynert, and in the locus ceruleus, 
and in cortical neurons in PD brains.68 A characteristic topographic spread of LB 
pathology in the brain has been proposed by Braak69 starting in the brain stem and 
progressing through 6 stages of the disease eventually spread to the neocortex. 
According to this theory, in stage 1-2 the LB pathology is confined to the 
medulla/pontine tegmentum and anterior olfactory structures. Stage 3-4 is 
characterised by initially subtle, but later severe changes of the substantia nigra and 
other nuclei of the basal mid- and forebrain including limbic structures. The disease is 
thought become clinically manifest during these stages. A 60 % to 80 % loss of 
dopaminergic terminals is needed to induce parkinsonian symptoms.70, 71 Stages 5-6 
are considered to be the final stages, when lesions appear in the neocortex.67 The 
duration of the preclinical stage of PD is unknown, but may last for 6-8 years.  
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Neurochemical dysfunction 
PD is a multi-system disorder that not only affects nigral dopaminergic nerve cells. 
Also other transmitter systems are affected. Reduced activity in cholinergic, nor-
adrenergic, serotonergic and glutamatergic transmitter systems have also been 
found72 Post mortem and in vivo studies of PD patients have found reductions in 
cholinergic activity in PD patients compared to normal controls and AD patients,73 
and dysfunction of the cholinergic system in the frontal cortex of patients with PD 
has been found to be associated with dementia.73, 74 
Several neuropathological criteria for PD exist. Those proposed by Gelb75 are as 
follows:  
• Substantial nerve cell depletion with accompanying gliosis in the substantia 
nigra  
• At least 1 Lewy body in the substantia nigra or in the locus ceruleus  
• No pathological evidence for other diseases that produce Parkinsonism (e.g. 
progressive supranuclear palsy, multiple system atrophy, cortical–basal 
ganglionic degeneration).  
Diagnosis of PD  
Parkinsonism is defined as the presence of bradykinesia/akinesia, rigidity , postural 
instability and tremor.76 Parkinsonism is found not only in idiopathic PD, although 
this is the most common cause of parkinsonism, and therefore misdiagnosis may 
occur. Important differential diagnoses to idiopathic PD are drug induced 
parkinsonism, Wilson’s disease, vascular and other neurodegenerative diseases like 
multiple system atrophy (MSA) and progressive supranuclear palsy (PSP).77 
The diagnosis of PD is based on clinical examination. To improve the diagnostic 
accuracy of the clinical diagnosis, criteria have been developed. The Stavanger PD 
diagnostic criteria differentiate between clinical definite, probable and possible PD to 
enhance sensitivity while retaining good specificity.78 The diagnosis of clinical 
definite idiopathic PD requires asymmetrical presentation and the patient must have 
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tremor. In addition at least two of the following symptoms are required: rigidity, 
bradykinesia or postural abnormality. Good to excellent response to dopaminergic 
agents is required and at disease onset no atypical signs should be present and CT or 
MRI of the brain is without major pathology. 
For a diagnosis of clinical probable idiopathic PD two of the cardinal symptoms must 
be present, and no more than one atypical feature is allowed: (1) dementia or 
clinically relevant autonomic failure at disease onset, (2) symmetrical disease 
presentation, (3) moderate response to dopaminergic treatment, or (4) other atypical 
signs or symptoms that indicate another parkinsonian disorder. 
For a diagnosis of clinical possible PD the patients must fulfil at least two of the four 
cardinal symptoms and the response to dopaminergic treatment should at least be 
moderate. Mild to moderate dementia and autonomic failure is allowed.  
The United Kingdom Parkinson’s Disease Society Brain Bank Diagnostic Criteria, 
are probably the most widely used criteria.79 The criteria described by Gelb are also 
widely used, and include neuropathologic criteria for a diagnosis of definite PD.75 
Clinical criteria have limitations in terms of diagnostic accuracy. Even in specialised 
centres, at least 15 % of patients with a diagnosis of PD did not fulfil strict clinical 
criteria for the UK Brain Bank criteria.80  
 
1.2.2 Cognitive impairment in PD 
Epidemiology 
Cognitive impairment is common even in newly diagnosed PD, affecting 25-30% of 
patients.81, 82 The pattern of cognitive deficits seen among these patients suggests that 
sub-groups of patients based on cognitive ability might be identifiable even in the 
early stages of disease, probably reflecting regional differences in the underlying 
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neuropathological processes.82 Cognitive impairment characteristically involves 
executive and visuospatial functions83 with deficits also in the memory domain.81  
Neuropathology of cognitive impairment in PD 
The neuropathologic/morphologic changes that accompany cognitive impairment in 
early PD are not known, but some functional changes have been found. In an fMRI 
study of working memory signal intensity reductions in specific striatal and frontal 
lobe sites in patients with cognitive impairment were found compared with those 
patients who were cognitively unimpaired. Cognitive deficits in PD are thus 
accompanied by neural changes that are related to, but distinct from, those changes 
that underlie motor deficits in these patients.84 
Another fMRI study showed decreased efficiency of prefrontal cortical information 
processing in the hypo-dopaminergic state and showed that dopaminergic therapy 
improved the physiological efficiency of this region.85  
 A PET study showed that reduced [18F] fluorodopa uptake in PD in the caudate 
nucleus (and frontal cortex) is related to impairment on neuropsychological tests 
measuring verbal fluency, working memory, and attention reflecting frontal lobe 
function.86  
These studies convincingly show that the dopaminergic system is associated with 
cognitive impairment in PD. They point to dysfunction in specific structures of the 
brain and to dysfunction of the dopaminergic system. However, these results do not 
exclude the possibility of more generalised changes in early PD with cognitive 
impairment or dysfunction in other transmitter systems. 
 
Diagnosis of cognitive impairment in PD 
The term mild cognitive impairment (MCI) describes a transitional state between the 
cognitive changes of ageing and the earliest clinical manifestations of dementia.87 
The prevalence of MCI in adults older than 65 years ranges from 3% to 19 % in 
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epidemiological studies. Some of them remain stable or return to normal, while more 
than half progress to dementia within a period of 5 years.88 
The most widely used diagnostic criteria of mild cognitive impairment are those 
proposed by Petersen;89 (a) complaint of defective memory, (b) normal activities of 
daily living, (c) normal general cognitive function, (d) abnormal memory function for 
age, and (e) absence of dementia. Recently MCI divided into subtypes has been 
proposed90 with the idea that subtypes of MCI can predict conversion to different 
types of dementia.91 Although diagnostic criteria for MCI have not been validated for 
PD, recent studies have employed Petersen’s criteria and found that in a study of 
patients with long duration of PD, over 50 % of the non demented subjects fulfilled 
these criteria92 and 62 % of them developed dementia over a 4 year period.93 Thus, 
the presence of MCI in PD seems to identify patients with a high risk of developing 
dementia. 
1.2.3 Dementia in PD 
Epidemiology  
There is an increased risk of dementia associated with the diagnosis of PD,94 with an 
almost six fold increased risk of becoming demented compared with subjects without 
PD.95 In cross-sectional studies, the prevalence is approximately 30%.96 In two 
longitudinal studies the reported cumulative prevalence of PDD was as high as 83%97 
and 78 %.98 
 Predictive factors for developing dementia in PD are age, severity of motor 
symptoms and cognitive impairment.41, 95 PD patients who develop postural 
instability and gait disorder (PIGD) during the course of the disease also have a 
highly increased risk for subsequent dementia. These findings raise the question 
whether these motor symptoms and dementia share common or parallel 
neuropathology.99 Early hallucinations and akinetic-dominant PD are associated with 
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an increased risk of dementia,98 but duration of PD and age at onset of PD are not 
predictive of dementia development.94, 100 
Patients with dementia in PD have more neuropsychiatric symptoms,101 including 
cognitive fluctuations, visual and auditory hallucinations, depression, and sleep 
disturbance.97 Dementia in PD has wide-ranging effects on quality of life of patients 
and caregivers, prognosis including the risk of nursing home admission and clinical 
management,102 and thus should become an important target in the treatment of the 
disease.  
Diagnosis of dementia in PD 
Dementia in PD (PDD) is characterised by executive dysfunction, visuospatial 
dysfunction , cognitive and motor slowing, impaired memory retrieval, and 
behavioural symptoms.83, 102, 103 Dementia in PD is often considered a sub-cortical 
dementia, although recent evidence show that the syndrome is heterogeneous and that 
both cortical and subcortical features occur.104 There are currently no specific and 
operationalised criteria for dementia in PD. According to the DSM IV criteria, PDD 
is diagnosed as “dementia due to other medical condition “. In brief, dementia is 
defined as the development of multiple cognitive deficits manifested by both memory 
impairment and one or more of the following disturbances aphasia, apraxia, agnosia 
and disturbance of executive functioning. These deficits cause significant impairment 
in social or occupational functioning and representing a significant decline from a 
previous level of functioning, and do not occur exclusively during the course of a 
delirium. No specific criteria for PDD are listed, but the typical features and the 
differential diagnoses are described.103  
 Diagnostic criteria for dementia in PD are currently being developed by a Task Force 
recruited by the Movement Disorder Society (MDS), based on a comprehensive 
literature review.105 These new criteria include criteria for probable PDD and possible 
PDD. PD is diagnosed according to the UK Brain Bank criteria as one of two core 
features. The second core feature is a dementia syndrome with insidious onset and 
slow progression, developing within the context of established PD and diagnosed by 
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history, clinical and mental examination, defined as impairment in more than one 
cognitive domain, representing a decline from premorbid level, with deficits severe 
enough to impair daily life (social, occupational or personal care), independent of the 
impairment ascribable to motor or autonomic symptoms.  
Causes of dementia in PD 
The cause of dementia in PD is incompletely understood but it is thought to be a 
multifactorial process involving multiple neuronal populations both cortical and 
subcortical.102, 106 Most recent neuropathological studies suggest that cortical and 
limbic Lewy bodies are the pathological changes associated with dementia in PD,107; 
108-110
 and that LB pathology in frontal and limbic areas correlate with the severity of 
dementia in PD.111 However, there are cases with PDD with rather mild LB 
involvement,108 and vice versa: some patients have marked cortical LB involvement 
but without dementia.112 Therefore, other factors than the absolute number of Lewy 
bodies in the neocortex and limbic system may influence the development of 
cognitive impairment in PD. Alzheimer type changes, in particular amyloid plaques 
may contribute,113 although they are found to be modest110 and not sufficient to fulfil 
the diagnostic criteria for AD.109, 114 The impact of vascular pathology for PDD is less 
studied. Although vascular changes are common in older people, they are not 
common in PD, and do not seem to be important for the development of dementia in 
PD.115, 116 
The variety of clinical and pathological features of PDD indicates that the syndrome 
is heterogeneous with individual differences. For example, more morphological 
changes were reported in PD patients developing dementia early in the disease 
compared to those with a late dementia.117 
Neurochemical deficits are also thought to have an impact on the development of 
dementia in PD, with loss of cholinergic, dopaminergic, and noradrenergic 
innervation.73, 118 Cholinergic markers such as Acetylcholine esterase is more reduced 
in the cortex of patients with PD than of patients with mild AD119 and choline 
acetyltransferase is more reduced in PDD compared to patients with DLB.117 In 
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summary, the main pathology underlying dementia in PD is Lewy-body-type 
degeneration with associated cellular loss in cortical and limbic structures and 
cortical cholinergic deficits. Further studies are needed to improve our knowledge 
about the causes of dementia in PD, and future studies should focus on in-vivo 
investigations as most previous studies have been based on the neuropathology of 
end-stage PD.  
1.2.4 Related dementias 
Dementia with Lewy Bodies 
DLB is reported by many as the second most common type of dementia after 
Alzheimer’s disease120 Clinically DLB is characterised by progressive cognitive 
impairment, recurrent episodes of confusion, attention deficits, parkinsonism and 
visual hallucinations.29 
DLB is characterised by cortical, limbic and brainstem Lewy Bodies, usually in 
combination with Alzheimer type changes.121 There is limited knowledge about the 
relationship between neuropathological findings and the clinical symptoms in DLB, 
and even less is known about the relation between in-vivo findings and the clinical 
phenotype.  
The diagnostic accuracy of DLB has been poor122 with low sensitivity of the first 
diagnostic criteria.123 New pathologic and clinical criteria are introduced to improve 
the accuracy of the diagnosis.29 Features suggestive of DLB now include REM sleep 
behaviour disorder and severe neuroleptic sensitivity. Recently visualisation of the 
striatal dopamine transporter is shown to aid in this distinction,124 and has been 
included in the revised criteria for DLB. Whether these criteria have improved 
diagnostic sensitivity remains to be seen. 
The dementia profile of DLB is similar to that of dementia in PDD,125 and the 
distinction between them is based on the relative timing of dementia and 
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parkinsonism.29 Patients presenting with less than 1 year of parkinsonism prior to 
dementia are diagnosed with DLB, whereas patients with > 1 year duration of 
parkinsonism prior to dementia are diagnosed with PDD. DLB can be difficult to 
distinguish from AD in early dementia. However, few studies have compared brain 
changes in PDD with DLB brain changes, although in a recent neuropathology study, 
differences were found in the severity of morphological and neurochemical 
changes.117 
Alzheimer’s disease 
Alzheimer’s disease (AD) is the most frequent cause of dementia and incidence rates 
increases with age.126 The typical symptoms of AD are insidious in onset and consist 
of progressive impairment of memory typically accompanied by aphasia, agnosia and 
apraxia, leading to impaired activities of daily living. In addition alterations in mood, 
and behavioural functions are common, like decline in emotional control or 
motivation and changes in social behaviour.103  
Increased risk of AD is associated with age and the apolipoprotein E e4 genotype. 
Educational level is inversely associated with the risk of dementia, and some find an 
increased risk for AD in women.126 
AD is characterised histopathologically by neuron loss and extracellular amyloid 
deposits and intra-neuronal neurofibrillary tangles in the brain.127, 128 The disease 
usually begins in entorhinal cortex and hippocampus, and subsequently involves 
temporal and parietal association areas.127 
The most commonly used clinical criteria for the diagnosis of AD, are the National 
Institute of Neurological and Communicative Disorders and Stroke and the 
Alzheimer’s Disease and Related Diseases Association (NINCDS-ADRDA) 
criteria,129 with good sensitivity (92%) and moderate specificity (65 %).130 The 
Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria and ICD 10 
criteria are other commonly used clinical criteria. 
(http://www.who.int/classifications/apps/icd/icd10online/ )  
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1.3 Imaging in Parkinson’s disease and in dementia 
associated with PD 
1.3.1 Imaging in PD 
Structural imaging techniques 
There is no single measure or imaging characteristic that is sensitive and specific for 
the diagnosis of PD. Therefore routine diagnostic imaging in patients with suspected 
idiopathic PD is done to exclude other potential causes of parkinsonism such as 
vascular parkinsonism, and may help in distinguishing PD from other 
neurodegenerative syndromes with parkinsonism like MSA and PSP.  
Studies have tried to find characteristic abnormalities to differentiate between 
Parkinson disease and its differential diagnoses. Pathology thought to be typical of 
MSA like putaminal hypointensity, lateral slit like hyperintensity and cerebellar 
abnormalities have also been shown in PD. However, these changes were always 
considered to be mild. Brainstem and putaminal atrophy was only seen in MSA.131 A 
similar study did not confirm these results, but showed that measurement of the 
middle cerebellar peduncle differed between PD, normal controls and MSA 
patients.132 The most recent attempt to develop a diagnostic tool for PD used a 3 tesla 
(T) MRI scanner and visualised neuromelanin-containing neurons in the brainstem 
locus ceruleus and substantia nigra pars compacta of healthy volunteers and patients 
with PD. In PD patients, the signal intensity in the locus ceruleus and substantia nigra 
pars compacta was greatly reduced, suggesting depletion of neuromelanin-containing 
neurons.133 Whether this method can differentiate between PD and other diseases 
with parkinsonism remains to be shown.  
Diffusion tensor imaging of the olfactory tract have shown promising results in 
distinguishing PD patients from normal controls,134 but more and larger studies are 
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needed to confirm their results, and to see if this method can serve as a biomarker in 
PD.  
Functional imaging techniques 
Novel functional imaging techniques are increasingly used in studies of PD for the 
evaluation of disease progression, disease severity, and to assess the effect of 
therapeutic intervention. Positron emission tomography (PET) and single photon 
emission computed tomography (SPECT) using dopamine tracers are among the most 
frequently used techniques. 
In PD patients the first perfusion SPECT studies did not find perfusion deficits 
compared to controls135, 136 while later studies have found brain hypoperfusion in the 
frontal lobes137 and multiple brain areas.138 Improved imaging techniques and 
methods of analysis may explain these differences, while differences in cognitive 
functioning might influence the results although they were all classified as not 
demented. 
With dopamine transporter (DAT) imaging by SPECT, and different ligands such as 
[123I]beta-CIT, loss of dopamine transporter in PD is depicted as a marker of loss of 
presynaptic dopaminergic neurons.139 This method is useful for differentiating PD 
from other parkinsonian syndromes,140 and DLB from AD.141 It may also aid in the 
discrimination between diseases that both have dopamine transporter loss like PD and 
MSA through quantification of midbrain DAT signal,142 but these results awaits 
confirmation by other studies. 
Functional imaging of the heart using the radionuclide Metaiodobenzylguanidine 
(MIBG), which is a specific marker for noradrenergic transporters, is significantly 
reduced in PD.143 This method, which until now have mostly been used in Japan, 
have also been shown to differentiate between LB related and non LB related 
dementia with a high sensitivity ( 95 %) and specificity (87 %),144 and may thus aid 
in differential diagnosis of patients with dementia. 
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1.3.2 MRI findings in PD with cognitive impairment and dementia 
Region of interest based methods. 
The first MRI studies of neurodegenerative diseases mainly involved the examination 
of specific structures thought to be most affected in the disease. In an early study, 
morphological measurements of the brain in 68 PD patients were done and compared 
to healthy controls. The authors concluded that dementia in PD is not associated with 
any specific pattern of MRI abnormalities.145 A subsequent study showed that PDD 
patients had hippocampal atrophy, and that this patient group had hippocampal 
volumes smaller than AD patients. PD patients without dementia also had 
hippocampal atrophy, but less pronounced than the PDD group.146 Later studies have 
confirmed the finding of hippocampal atrophy in both PD groups,147 but it has not 
been found to be more severe than in AD patients.148 A pattern of the severity of 
hippocampal atrophy has been proposed; (Control < PD < PDD <DLB< AD) 
suggesting progressive hippocampal volume loss in PD.149 Atrophy of the amygdala 
and prefrontal cortex has also been shown in PDD.147, 150 
In addition studies have reported caudate atrophy in AD and PDD but not PD, 
suggesting that caudate atrophy is part of a general brain atrophy rather than being 
regionally specific.151  
Methods for assessing volumetric and regional changes using unbiased 
methods. 
The first study to compare whole brain atrophy in PD versus other types of dementia 
was published in 2004152 showing that the pattern of grey matter loss in PD and PDD 
was different from the changes found in AD. They found occipital atrophy in the 
PDD group and frontal volume loss in PD without dementia. The AD group had more 
temporal lobe atrophy, including the hippocampus and parahippocampal gyrus 
compared with the PDD group. No difference in grey matter volume was found 
between PDD and DLB patients. Their results in PD patients were confirmed, while 
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the changes found in PDD differed in another study. They did not find occipital 
atrophy in PDD, rather they found widespread atrophy of the limbic/paralimbic 
system and the temporal lobe, dorsolateral prefrontal cortex and the parahippocampal 
gyrus.153 A third VBM study, which did not include the whole brain154 found that the 
hippocampus, thalamus and anterior cingulate are the regions most affected in PDD. 
Each of these studies involved rather small samples and therefore further studies are 
needed to confirm their findings and add to the knowledge about grey matter changes 
in PD.  
Longitudinal studies 
Few studies have addressed the longitudinal brain changes in PD using imaging. 
A study by Paviour showed the annual overall atrophy rate of PD to be 0.6-0.7%,16 
while other investigators found annual percentage loss of 0.8 %.155 The annual rate of 
atrophy found in PDD was 1.1 %.156 In comparison, in DLB the atrophy rate was 
found to be 1.4 %. In this study the rate of atrophy in DLB was not found to be 
significantly different from AD.36 A annual atrophy rate of about 2 % per year has 
been found in patients with AD.15 An accelerating atrophy with increasing severity of 
dementia has been suggested for AD, vascular dementia and DLB36, 157but this has 
not been found in PD/PDD.156 The pattern of general atrophy rate among the 
neurodegenerative diseases is thus similar to that of hippocampal atrophy: Control  
PD < PDD <DLB< AD. 
The studies above did not look at the regional differences in atrophy during the 
follow up period. One longitudinal VBM study has looked at regional differences in 
grey matter volume loss in PD patients with and without dementia with disease 
progression. They found a widespread decrease in limbic and paralimbic regions in 
non-demented patients. Neocortical volume reduction was the most relevant finding 
in patients with dementia.158 Based on this study the authors suggested that the 
neocortex is the substrate for dementia in PD. This was a small study (19 subjects) 
and had a short follow up time (25 months). Future studies should include more 
patients followed for a longer period.  
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The impact of T2 WMH lesion progression on global cognitive performance has 
recently been studied. The authors found a 0.07 % increase of WMH volume in PDD 
patients, but no association with this increase and change in global cognitive 
performance.159  
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2. Hypotheses 
1. The frequency and extent of white matter T2 hyperintense lesions (WMH) are 
associated with dementia in PD.  
2. The pattern of grey matter atrophy in PD is different from atrophy in normal 
ageing, and is associated with the severity of cognitive impairment. 
3. Grey matter atrophy in patients with PDD differs from the pattern of atrophy in 
patients with Alzheimer’s disease but not from patients with Dementia with Lewy 
Bodies. 
4. Patients with PD who develop dementia early in the disease diagnosis have more 
grey matter atrophy than patients who develop dementia late in the disease course. 
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3. Methods 
3.1 Subjects 
3.1.1 Patients 
Patients were recruited by doctors in the outpatient clinics of the Department of 
Neurology, Department of Geriatric Medicine and the Department of Old Age 
Psychiatry at Stavanger University Hospital in the period from 2001 to 2005. One 
group was recruited from an ongoing longitudinal study, the Parkinson-study of 
Rogaland, during their annual follow up (n= 17). Another group consisted of 
consecutive patients with PD with and without dementia, and patients with 
Alzheimer’s disease and DLB. They were diagnosed as described below. 
3.1.2 Controls 
Healthy elderly volunteers were recruited from Stavanger and the surrounding district 
after information in meetings arranged by local clubs for the retired, meetings for 
patients and relatives of patients with either dementia or PD. Some volunteers also 
recruited others and some healthy controls were relatives of my friends or colleagues.  
They were interviewed for information about medication, education, previous illness 
including psychiatric illness, and a mini mental state examination (MMSE) was 
done.160 
 38 
3.1.3 Inclusion/exclusion criteria 
Inclusion criteria 
Patients were included after all information about the patient was evaluated by an old 
age psychiatrist (DAa) and the patient was found to fulfil the diagnostic criteria of 
PD, PDD, AD or DLB (see below), and agreed to participate after the procedure was 
explained in full. Clinical assessments were, performed by a study neurologist and/or 
a psychiatrist with experience in neuropsychiatric research. Cognitive assessments 
were performed by a trained research nurse. 
Exclusion criteria 
We excluded patients with any neurological or psychiatric disease other than PD, AD 
or DLB that could potentially be the cause of their dementia. (e.g. significant 
cerebrovascular disease, space occupying intracranial lesion, uncompensated 
hypothyroidism or vitamin B12 deficiency, substance abuse, or other severe 
psychiatric illness (e.g. schizophrenia). 
Focal lesions affecting grey matter led to exclusion from the VBM studies. The MRI 
scans were thus checked before inclusion of a patient or control person. Those who 
had structural abnormalities in the brain affecting grey matter were excluded from 
VBM analysis. Subjects with marked tremor or dyskinesia which interfered with the 
imaging session were also excluded from the VBM studies because the scans could 
not be correctly segmented into grey matter, white matter and cerebro spinal fluid 
(CSF). Some of these patients were included in the study of white matter 
hyperintensities, since for this visual rating we used T2 weighted images and for 
these sequences some patient movement was not critical for the evaluation of the 
lesions.  
 
 39 
3.2 Clinical assessments 
3.2.1 Cognition 
A semistrictured interview using the DMS IIIR or DSM IV criteria for dementia103, 161 
as a guide was administered. All patients performed a MMSE, a brief and widely 
used cognitive screening test. The MMSE assesses orientation, learning, short term 
memory, concentration and higher cortical functions through an interview containing 
30 questions/tasks. It is mainly used to differentiate between cognitively intact, and 
cognitively impaired patients.160 In addition, patients completed the Dementia Rating 
Scale162 or the CAMCOG, the cognitive battery of the CAMDEX.163  These more 
comprehensive screening instruments include a more detailed assessment of 
executive functions than MMSE.  
3.2.2 Motor and psychiatric measures 
Motor symptoms : The clinical evaluation of motor symptoms consisted of the 
motor subscale of the Unified PD Rating Scale (UPDRS),164 including the Hoehn & 
Yahr scale.165 
Psychiatric symptoms: Psychiatric symptoms were assessed using the 
Neuropsychiatric Inventory (NPI),166 a structured care-giver based clinical interview 
designed to elicit psychiatric symptoms in subjects with brain damage and cognitive 
impairment. In addition, depression was assessed by a psychiatrist or a research nurse 
using either the Montgomery Åsberg Depression Rating Scale (MADRS)167 or the 
NPI. The main purpose of the psychiatric assessment was two-fold: First to seek 
information for the diagnosis of DLB, i.e. visual hallucinations, and second to 
differentiate between depression-induced cognitive impairment and dementia. 
 40 
3.2.3 Supplemental tests 
As part of a routine dementia work up a clinical examination, the history of previous 
physical or psychiatric diseases was recorded and a physical examination including a 
neurological examination was performed. Routine blood analysis, including thyroid 
status, folate and cobalamine status was done on all patients. If there was a clinical 
indication ECG and supplemental tests like a chest x –ray, or perfusion SPECT of the 
brain was done. To ascertain the diagnosis of DLB, dopamine transporter imaging 
was performed on 11 patients with a clinical diagnosis of DLB. 
3.3 Diagnostics 
3.3.1 Diagnosis of PD  
For the diagnosis of PD the diagnostic criteria from Stavanger were used.78 These 
criteria are described in detail in section 2.1.5. Patients with clinically significant 
cognitive impairment at disease onset were excluded, to avoid diagnostic overlap 
with DLB. 
3.3.2 Diagnosis of MCI in PD 
A Diagnosis of MCI was made according to a modified version of the criteria 
proposed by Petersen89 Impaired performance on neuropsychological tests was 
defined as 1.5 standard deviations (SD) or more below the mean of the control group. 
Impaired performance on one, two or all three tests was required for a diagnosis of 
MCI. The three neuropsychological tests used were; the multiple choice version of 
the Benton Visual Retention Test, (BVRT)168 the Judgement of Line Orientation test 
(JLO)169 and the Stroop Word Test (SWT).170  
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Through a caregiver-based interview, information about memory complaints or other 
cognitive complaints was collected. If cognitive impairment was present, but not 
serious enough to affect activities of daily living the patients were classified as 
having MCI.93  
3.3.3 Diagnosis of dementia in PD 
In this study the diagnosis of PDD was made in a patient fulfilling PD criteria who 
also fulfilled criteria for dementia based on the Diagnostic and Statistical Manual of 
Mental Disorders (DSM III –R)161 or (DSM IV) criteria for dementia103 based on the 
clinical interview and cognitive assessment, given that no other plausible explanation 
for the dementia syndrome was found. Patients were examined by a psychiatrist and a 
research nurse, both experienced in dementia evaluation. Patients with a notable 
cognitive impairment before or within 1 year after onset of PD were not included in 
the PDD group.  
3.3.4 Diagnosis of DLB and AD 
Dementia diagnoses were made after a clinical interview with the patient and a care-
giver and supported by neuropsychological testing and supplementary tests including 
brain imaging to exclude other causes of cognitive decline. AD was diagnosed 
according to the National Institute of Neurological and Communicative Disorders and 
Stroke and the Alzheimer’s Disease and Related Diseases Association (NINCDS – 
ADRDA) criteria for a diagnosis of probable AD,129 and probable DLB was 
diagnosed according to the criteria suggested by the third report of the DLB 
Consortium.29  
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3.4 MRI and image analysis 
3.4.1 MRI imaging protocol 
All patients and healthy elderly volunteers are scanned at Stavanger University 
Hospital, department of Radiology. The first healthy elderly were scanned in 
December 2001 in a Phillips gyroscan NT intera, Release 8.1 MRI machine (Philips 
Medical Systems, Best, the Netherlands. This was later upgraded to release 10.3.1, 
which was an upgrade of the platform for the operating system, and had no effect on 
the image quality. All patients and controls are imaged in the same MRI scanner. The 
following imaging protocol was used; A coronal T1- weighted 3D fast spoiled 
gradient recalled echo (FSPGR), resulting in 124 coronal slices (repetition time(TR) 
12,4 ms, echo time (TE) 4,2 ms, inversion time (TI) 650 ms, matrix 256x192, slice 
thickness 1,6 mm). In addition the following sequences were acquired (Sagittal T1, 
axial dual fast field echo (FFE), coronal T2 fluid attenuation inversion recovery 
(FLAIR). The same head position and imaging protocol was used for all the 
participants of this study. Our imaging protocol was mainly composed of our 
standardised protocol for brain imaging with an additional 3D series created after a 
protocol used for VBM studies in Newcastle General Hospital, England. This led to a 
total scan time in the machine of ~30 minutes. Because we observed that tremor 
tended to increase during scanning, we acquired the volumetric sequence first. 
3.4.2 Visual rating of white matter T2 hyper-intense lesions 
Several methods exist for the evaluation of white matter T2 hyperintense lesions in 
MRI images. We have used the semiquantitative method published by Scheltens in 
1993171 which was one of the first methods after Fazekas172 to try to give a measure 
for the load of lesions. I was taught the method of Scheltens by Emma Burton, PhD, 
Wolfson Research Centre, Institute for Ageing and Health, Newcastle General 
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Hospital, UK, who had research experience in using this method. We used the 
scoring sheets obtained from Newcastle. Two radiologists did the rating of WMH in a 
blinded manner. A proportion of the images were rated twice during the same session 
for the evaluation of intra rater reliability. Both raters rated each scan two times with 
a time interval of 1-2 weeks between ratings. These ratings were used to establish our 
inter-rater reliability. Through consensus sessions we decided on the results of each 
patient, also blinded regarding name, diagnosis and age etc. These results were then 
used in the group analyses for the load of WMH. 
Periventricular WMH was scored according to the following criteria; 
Absence of lesions give a 0 score,  5 mm lesion = score 1, and score 2 is rated if the 
lesion is > 5mm. Hyperintensities exceeding 10 mm were scored as lobar white 
matter changes. 
 
WMH located in the deep and subcortical white matter was rated according to the 
following criteria;  
Score 0 = no abnormalities 
Score 1 = lesions less than 3mm,  5 lesions,  
Score 2 = lesions < 3mm, 6 or more lesions, 
Score 3 = lesions 4-10 mm,  5 lesions 
Score 4 = same as 3, but 6 or more lesions 
Score 5 = lesions > 11mm, > 1 lesion  
Score 6 = confluent lesions. 
These rating criteria were applied to regions of the deep white matter (frontal, 
parietal, occipital, and temporal), and also for the basal ganglia and infra-tentorial 
foci of WMH. 
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For the statistical analysis, the SPSS statistics package, version 11.5 (SPSS for 
Windows, Release 11.50 (6 Sep 2002) SPSS Inc)) was used. Differences between 
groups on continuous variables were first assessed using bivariate analyses, 1-way 
analysis of variance (ANOVA) with post hoc Scheffes test to determine group 
differences. For the non-parametric data a Kruskal Wallis test was used followed by a 
post hoc Mann Whitney U test, or a chi-square test was used when appropriate. 
Multivariate regression analyses were performed to assess the relationship between 
WMH and cognition in PD after controlling for potential confounding variables. 
These potentially confounding variables included age, sex, education, Hoehn & Yahr 
stage, cerebrovascular risk factors. For cognition the MMSE score was used as a 
measure. 
This was the first time we used the rating scale of Scheltens,171 therefore we needed 
to assess our reliability. Several methods are developed to evaluate reliability. We 
used the intraclass correlation coefficient (ICC) for the evaluation of intra – and inter 
rater reliability. The ICC is considered as poor when below 0.4, fair to good between 
0.4 and 0.75, and excellent for values above 0.75.173  
5.4.3 Voxel Based Morphometry (VBM) 
In 2000 VBM was introduced as a method for analysing whole brain structural 
images.174 Although even prior to this the method had been described.175 
Morphometric methods attempts to automatically identify neuroanatomical 
differences, using VBM the analyses are among groups of brains. 
To prepare the images for statistical analyses a series of pre-processing steps must be 
done. The “optimised ” VBM was developed to improve the spatial normalisation of 
the images, and to better remove non-brain tissue during segmentation.10 This 
approach has later been widely used. We have used this approach in the VBM studies 
included in this thesis, and the description of image pre-processing below refers to 
this method, which is also shown in the flow chart below (Figure 2). 
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T1 image Affine registration 
Affine transform 
Segmentation and 
extraction 
GM/WM image 
Spatial normalisation 
Apply deformations 
Deformation field 
T1 template 
GM/WM/CSF 
priors 
Normalised T1 image 
Segmentation 
and extraction 
GM/WM image 
Smooth 
Preprosessing steps as described by Good et al 
Statistics 
(concentrations) 
 
Figure 2. Flow chart describing the steps of pre-processing MR images in VBM.  
 
Template creation and pre-processing steps  
For SPM2 customised templates based on all the patients and controls in the study are 
created. This is important when studying older people with brain atrophy and larger 
ventricles that make them different from templates provided with the software, which 
are usually based on younger persons. An example of this is the illustration below, 
which shows the difference between our customised template and the template from 
SPM2.  
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Default template Customised template 
 
Figure 3. Left: The image shows the default template of SPM based on younger persons 
Right: the customised template created for this study based on all patients and healthy 
controls. Note that the size of the ventricles and the width of the sulci are larger in the 
customised template, based on older persons.  
 
We created a study specific T1 template image (based on all the patients and controls 
in our study), and a study specific grey matter template/prior probability map. The 
templates are made by averaging the spatially normalised tissue class images from all 
included subjects of the study.  
 The first pre-processing steps include the creation of customised templates. T1 
images of each patient were normalised to the T1 Template of SPM2 using an affine 
only cut-off. After normalising, images were averaged and then smoothed with an 
8 mm kernel, creating the T1 template. We then normalised the original images to the 
customised T1 template using a 25 mm cut off. The normalised images were then 
segmented and smoothed with an 8 mm kernel. The smoothed grey matter images 
were then averaged creating the study specific grey matter template. The resolution of 
the normalised images was high with 1.5mm isotropic voxels. These templates were 
used in the optimised VBM protocol in the following manner; 
The original images were segmented and the grey matter images were normalised to 
the customised grey matter template. The resulting deformations from the 
normalisation of grey matter to the grey matter template were used to normalise the 
original T1 images before the final segmentation. Segmented images were then 
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smoothed with a 12 mm kernel. The resulting smoothed images were used in the 
statistical analysis. 
Spatial transformations are applied to the images so that they all conform to a 
standard brain. 
Smoothing of the images conditions the data so that they conform more closely to a 
Gaussian field model, i.e. if you want to make statistical inferences about the 
regionally specific changes 
Statistics in VBM 
Voxel based morphometry uses mass-univariate tests for comparing whole brain 
images. Each voxel is analysed using any standard (univariate) statistical test. That 
means that there is a single variable at each voxels in the analysis.176 The resulting 
statistical parameters from these analyses are assembled into an image –the Statistical 
Parametric Map (SPM). Standard statistical procedures are done within the 
framework of the general linear model.  
 SPM has been used and developed mainly for analysis of functional imaging data, 
but with VBM structural data can also be analysed. To be able to apply voxel based 
analysis of imaging data, spatial transformations are applied to the images so that 
they all conform to a standard brain. This is called normalisation, and this facilitates 
the reporting of the results in a conventional way. The smoothing of the images 
conditions the data so that they conform more closely to a Gaussian field model. The 
Gaussian Random Field determines the number of independent statistical tests which 
makes it possible to correct for multiple comparisons. The smoothing also renders the 
data more normally distributed, increasing the validity of parametric statistical 
tests.176 
After analysing the images, SPM shows regions where grey matter concentration 
differs significantly among groups. This is if unmodulated images are analysed.  
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MNI and Talairach space 
The co-ordinates of the significant peak voxels ( i.e. the voxel that has the highest z/T 
score among the voxels surviving the threshold) are in MNI space. MNI space is an 
internationally distributed brain template from Montreal Neurological Institute, 
Canada based on 152 normal brains that is used as standard template brain for SPM2. 
(http://imaging.mrc-cbu.cam.ac.uk/imaging/MniTalairach) The co-ordinate system of 
MNI space differs from another brain template, the Talairach template brain.177 Both 
templates can be used to find the localisation of significant voxels in SPM. There are 
also conversion algorithms from MNI to Talairach space, which I have used in my 
publications with VBM (http://imaging.mrc-cbu.cam.ac.uk/imaging/MniTalairach) 
Having found the localisation of the peak significant voxel using either MNI or 
Talairach space, the anatomic name of the area where this voxel is situated can be 
found using either an atlas177 or using one of several online anatomical atlases e.g. 
Talairach Daemon.178 
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4. Results 
Table 1. This overview provides the demographic characteristics of the different 
patient groups who took part in the present study. All mean values are shown with the 
standard deviations in parenthesis.  
 PD no 
dementia 
PDD AD DLB Healthy 
controls 
Subjects (n) 19/20g 15 /16 a 21 18 20 
Female (n) / male (n) 11 / 9 5 / 10 16 / 5 9 / 9 10 / 10 
Mean age (years) 72.5 (8.5) 73.3 (6.5) 75.1 (9.2) 78.3 (5.8) b 73.6 (6) 
MMSE score  28.2 (2.1) 19.3 (4.7) 20.0 (5.0) 19.4 (4.9) 29.6 (0.7) c 
Education (years) 11.0 (3.6) 9.9 (3.6) 8.2 (2.2) 8.3 (2.1) 12.1 (4.3) d 
Hoehn & Yahr stage 2.4 (0.6) 3 (0.5) e - 2.4 (1.6) NA 
PD duration (years) 12.0 (6.3) 12..3 (7.5) NA 3,6 (1.8) NA 
PD years prior to dementia NA 9.9 (7.2) NA 0.5 (0.5) NA 
Duration of dementia (years) NA 1.9 (1.1) f 2.9 (1.4) f 3.7 (2.2) f NA 
 
NA = non applicable 
a
 One of the patient included in paper 1 and 2 was excluded from paper 3 and 4 (see discussion).  
b
 The DLB group was significantly older than the PDD (p=0.036) and control (p=0.028) groups. 
c
 The MMSE score in the PDD group was lower than in the PD without dementia - and control groups. 
d
 Education was longer in the control group than in AD (p<0.001 ) and DLB (p=0.002) groups. 
e
 A higher H &Y stage in PDD patients than in PD patients was observed. 
f
 Dementia duration was shorter in PDD than in AD (p=0.03) and in DLB (p=0.007) groups. 
g
 Only 19 PD patients in paper 1, as one was recruited after the analyses for this paper.  
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4.1 Results paper 1  
Overall, WMH did not differ between PD and control subjects. However, compared 
to the non-demented patients, the PDD group had significantly higher level of WMH 
in the deep white matter (p=0.01) and in the peri-ventricular areas (p=0.03). WMH in 
the deep white matter was the only variable which was significantly associated with 
MMSE score (p=0.02) and explained 38 % of the variance in the multivariate linear 
regression analysis. Our findings suggest that WMH in the deep white matter may to 
some degree contribute to dementia in PD.  
4.2 results paper 2  
4.2.1 PDD versus controls. 
Patients with PDD had reductions in grey matter concentration in the limbic lobes 
(amygdala) and both temporal lobes, compared with the control group. On the left 
side there was also reduced grey matter density in the frontal lobe, limbic lobe 
(cingulate and hippocampus) and brainstem red nucleus. On the right side there was 
reduced grey matter density in the middle occipital gyrus. When we included age, 
gender and PD duration as covariates in ANCOVA the results were unchanged. There 
were no areas where controls had more grey matter atrophy than patients with PDD. 
Using a small volume correction and correcting for multiple comparisons the bilateral 
reduction of grey matter in the middle temporal gyrus and amygdala, and also the left 
brainstem red nucleus were significant at p FWE < 0.05. 
4.2.2 PDD compared with PD without dementia  
In PDD there were areas of significant grey matter reduction in frontal lobes, limbic, 
parietal and temporal lobes bilaterally. On the right side there was also reduced grey 
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matter density in the pulvinar of the thalamus. The results did not change when age, 
gender and duration of PD were included as covariates in ANCOVA.  
There were no areas where non -demented patients had more grey matter atrophy 
than patients with PDD.  
4.2.3 Group comparison of PD with and without MCI. 
PD patients with MCI had reduced cortical grey matter density compared with 
cognitively intact PD in the left middle frontal gyrus, precentral gyrus and in the left 
superior temporal lobe and right inferior temporal lobe. The findings were not 
significant after small volume correction and correction for multiple comparisons. 
When we analysed with age and gender as covariates in ANCOVA the differences 
were no longer significant, but when we analysed with duration of PD as covariate 
the same changes in grey matter were found as in the ANOVA. PD without MCI did 
not have any areas of more grey matter atrophy than PD with MCI.  
4.3 Results paper 3 
4.3.1 Comparison of PDD and DLB patients 
We found more pronounced cortical atrophy in DLB than in PDD in the temporal, 
parietal and occipital lobes. Using age as a covariate, there were areas of reduced 
grey matter in the temporal, parietal and occipital lobes, with increased atrophy in 
patients with DLB relative to PDD (p uncorrected < 0.001). Changes were found 
bilaterally in the inferior parietal lobule and in the precuneus. Areas with increased 
atrophy only in the right hemisphere were in the insula, inferior temporal gyrus and in 
the lentiform nucleus. Areas of increased atrophy found only in the left hemisphere 
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were in the angular gyrus, cuneus, and in the superior occipital gyrus (See figure 4). 
There were no areas with more atrophy in PDD than DLB. 
 
 
 
Figure 4. The figure shows the areas of grey matter atrophy in the DLB group compared 
to the PDD group. These are outlined as yellow areas overlaid on a structural MR image 
of the brain.  
4.3.2 Comparison of PDD and AD patients  
AD patients had reduced grey matter concentrations in the temporal lobes bilaterally, 
including the amygdala, compared to PDD. Compared with PDD, AD patients had 
reduced grey matter concentrations in the amygdala and middle temporal gyrus 
bilaterally (p uncorrected < 0.001). There were also reduced grey matter 
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concentrations in the right insula and postcentral gyrus. Left sided grey matter 
reductions were found in the hippocampus and middle occipital gyrus 
4.4 Results paper 4 
The early dementia group had areas of more atrophy than the group with late 
dementia. The areas of reductions in grey matter volume were bilaterally in the 
medial frontal gyrus, and in the right precuneus, and on the left side in the inferior 
parietal lobule, superior frontal gyrus and middle temporal gyrus. In the group with 
long disease duration prior to dementia we found symmetrical grey matter volume 
reduction in the inferior frontal gyrus bilaterally.  
In the unmodulated images, the group with early dementia had more atrophy than the 
group with late dementia in the striatum (right caudate, left putamen), in the left 
precentral gyrus, left middle temporal gyrus and in the right red nucleus. The late 
dementia group had symmetrical reduction in grey matter in the insula bilaterally 
compared to the early dementia group.  
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5. Discussion 
5.1 Main findings 
1. We have shown that white matter hyperintense lesions in T2 weighted series on 
MRI are not increased in number or extent in the total PD group compared to a 
control group. However, they were increased in number and extent in PDD compared 
to non-demented PD subjects.  
2. We found atrophy in PDD both in cortical and sub cortical grey matter compared 
to healthy subjects and non-demented subjects with PD. A novel finding was 
reduction in grey matter observed in patients with MCI and PD compared to subjects 
with PD and intact cognition. This finding indicates that even the early cognitive 
impairment in PD is associated with morphological changes.  
 3. The overall pattern of grey matter changes in PDD differed from that in AD and 
DLB, although overlapping regions of atrophy exists. DLB patients have more 
atrophy in parietal and occipital areas compared with PDD patients. 
4. We found that patients with PD who develop dementia early have a different 
pattern of atrophy than those who develop dementia late in the course.  
5.2 Methodology 
5.2.1 Patient selection 
Patients for this study were mainly recruited at the outpatient clinics of the 
department of Old Age psychiatry and the Department of Neurology. Some were 
recruited from the outpatient clinic of the Department of Geriatric Medicine. These 
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are the three main centres of referral for patients with PD and neurodegenerative 
diseases in our region. Even patients living in nursing homes attend the outpatient 
clinics, and all patients with PD have their follow up at the Department of Neurology. 
Compared to other samples of patients with AD, PDD and DLB, our groups are 
rather similar with regard to age, gender and MMSE,154, 179 although differences in 
duration of the disease exist. This suggests that our samples do not differ markedly 
from the overall populations of patients with AD, DLB and PDD.  
One source of selection bias is the fact that the patients had to be able to complete the 
MRI scanning, and those who had suffered from stroke or had lesions of grey matter 
were not included. This may have led to the selection of the patients with less 
vascular disease and tremor. However, also the healthy controls had the same 
exclusion criteria regarding lesions. For future studies patients with previous stroke 
could be included since there exists methods to overcome this problem by masking 
out the lesions, e.g.180 Patients with marked tremor will be a continuing problem for 
MRI scanning because it creates movement artefacts. 
Impact of groups differences 
The groups of patients included differed with regard to age, gender and education 
(see table 1) which may have influenced our results.  
A correlation between age and rate of atrophy has been shown for normal controls,156 
but in AD and DLB groups, variance in the rate of atrophy was more influenced by 
baseline MMSE than age.36 In PD patients no association between cognitive scores at 
baseline or age, and rates of atrophy was found, while atrophy was inversely 
correlated with UPDRS motor score at baseline in PDD patients.156 To my 
knowledge, no gender specific differences of atrophy in PD or DLB have been 
shown. In healthy elderly, more brain atrophy was found in male than female subjects 
with ageing. 181 In AD perfusion differences have been shown between male and 
female patients,182 and female patients with AD  have been found to have less atrophy 
than men.183 Increased atrophy has been shown in AD patients with more 
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education.183 The association between length of education on atrophy in PD/PDD and 
DLB is unknown.  
In some comparisons where only one of the possible confounds was different, we 
could include this as a covariate in the analysis. When more than one variable 
differed, a correction could not be done due to the small groups with low statistical 
power. The groups were however perfectly matched for MMSE, which is the most 
important factor. One may argue that since the MMSE is dominated by items 
assessing memory and language, it may not be the optimal method to match for 
overall severity of dementia between the groups. However, there is no consensus 
regarding the optimal method of matching different dementia groups, and the MMSE 
is the most common variable used for matching groups in dementia studies. In 
summary, although the groups were well matched regarding level of dementia, a 
possible bias due to demographic differences cannot be excluded. 
Cross sectional study 
This study is a cross sectional study. Accordingly, rate of atrophy and causality 
cannot be firmly established. However, there are good reason to believe that the more 
severe atrophy observed is causally related to differences in cognition, since several 
of the affected areas are implicated in cognitive functioning. We had planned to do 
follow up scans, but many of the patients died not long after the first scanning and we 
considered the number of surviving patients to bee too low. Future studies should 
scan PD patients at the time of diagnosis and follow them with annual clinical 
assessment and a follow-up scan after 2-3 years. We have incorporated this design in 
our new and ongoing study. 
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5.2.2 Diagnostics  
Diagnosis of PD  
The clinical diagnosis of PD is not 100% accurate, even by experienced clinicians. 
However the positive predictive value of the clinical diagnosis of idiopathic PD by 
movement disorder specialists in the UK was as high 98 % using the UK Brain Bank 
criteria.184 In this study, all PD patients were diagnosed by neurologists with a special 
interest in movement disorders, using explicit criteria for PD.78 These criteria were 
designed in order to achieve both high sensitivity (possible PD) and specificity 
(clinical definite PD). Only patients with a diagnosis of clinical probable or clinical 
definite idiopathic PD were included in this study. In another project from our 
hospital, all brains of patients with the clinical diagnosis of PD were confirmed as 
Lewy body PD by neuropathological examination.109 Since the same movement 
disorder specialists are involved in the clinical diagnosis and follow-up of PD in the 
two projects we expect the diagnostic accuracy to be high.  
Diagnosis of AD and DLB  
The diagnoses of AD and DLB were based on clinical examination and thus 
misdiagnosis may occur. We took care to ensure good diagnostic accuracy, however. 
All patients were assessed using a comprehensive battery of clinical examination, 
including standardised instruments for cognitive, psychiatric and neurological 
symptoms. The clinical examinations were performed by experienced and trained 
clinicians, psychologists, and research nurses and the final diagnoses were made by 
an experienced clinician based on all available information, including longitudinal 
follow-up evaluations after the scans were performed (not reported in the papers). For 
AD, the NINCDS – ADRDA129 criteria were used, which have shown good 
diagnostic accuracy with neuropathological diagnosis.130, 185  
The DLB diagnosis was made according most recent criteria from the DLB 
Consortium29. Only subjects with probable DLB were included. The previous criteria 
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for DLB by the DLB Consortium have shown low sensitivity in several studies but 
generally they have provided excellent specificity.120, 186 Thus, when a diagnosis of 
DLB is made, it is usually correct. To further ascertain the diagnosis, in some cases a 
DAT SPECT scan was performed. This examination is shown to have high sensitivity 
and specificity for a diagnosis of DLB versus AD,124, 187 and is  included as a 
supportive feature in the revised criteria for DLB29. To differentiate between PDD 
and DLB only subjects with several years of pure movement disorder prior to 
dementia were included in the PDD group. This is demonstrated in the observation 
that the mean duration of PD was 12 years, with less than 2 years duration of 
dementia (see table 1). Due to lack of pathological confirmation of the diagnoses we 
cannot exclude the possibility that subjects with diagnoses other than DLB and AD 
were included. 
Cognitive and neuropsychiatric assessment 
The assessment of cognition varied somewhat between diagnostic groups. This is due 
to the fact that subjects were recruited from different study populations. However, for 
all patients, standardised psychiatric and cognitive assessments using scales with 
established reliability and validity were administered.  
MCI and dementia in PD  
Criteria for MCI in PD have not yet been validated, and this is a novel concept.  We 
used a modified version of the criteria for MCI in the general population, but our 
criteria may not have been strict enough. We only had three neuropsychological tests, 
and impairment only in one test was sufficient to get a classification of MCI. This 
will lead to a risk for a false positive diagnosis. Nevertheless, patients with PD-MCI 
had more atrophy than those without MCI. There is a need to establish criteria for 
MCI in PD and a battery of tests to diagnose MCI in PD. Further support to our 
diagnosis of MCI was provided in a recent prospective follow-up study, 
demonstrating that subjects with PD and MCI, diagnosed with the criteria mentioned 
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above, had a higher risk of developing dementia than non-demented PD patients 
without MCI.93  
Pathological criteria for PDD do not exist, and thus we have to rely on a clinical 
diagnosis. Clinical criteria for dementia in PD have only very recently been proposed. 
In our study, we required a firm diagnosis of PD, and dementia according to DSM-
IIIR or DSM IV. The DSM-IIIR was used in the Rogaland PD cohort for consistency 
throughout the study. Our definition is in accordance with previous 
recommendations,120 and does not differ markedly from the recently proposed criteria 
for PDD (105In press). The accuracy of the diagnosis of dementia in PD as well as 
DLB is supported by the fact that all these patients are followed regularly at the 
outpatient clinic for participation in other research projects, and a rate of decline in 
PDD similar to that in AD has been observed.188   
One patient with PDD was included in the first two papers, but then not included in 
the last two. We followed these patients over time, and this patient had at one point a 
variation in test scores that led to discussion about the diagnosis of PDD. Therefore 
we chose not to include her for the last two papers. She later had test scores 
indicating that it was correct to include her in the PDD group in the first two papers.  
In the first paper 19 patients were included in the PD group. This was because the 
analyses for this study were done before inclusion for the VBM studies were finished. 
5.2.3 Scanning technique 
MRI scanning techniques are constantly improving and knowledge about the 
different possibilities increase through studies. When we started this project our main 
focus was to create a protocol for imaging that was fast enough for the patients to be 
able to complete. Especially the volumetric sequence is time consuming, but also the 
most important in our project. Thickness of slices is one of the ways to reduce 
scanning time. This study has 1.6 millimetre slices, while most studies now use 
1x1x1 millimetre isotropic voxels in their protocol. Improved techniques using 
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parallel imaging allows this to be done in 5-6 minutes now, while our volumetric 
series took more than 9 minutes. This will improve the image quality of future 
studies, and might affect the results. 
5.2.4 Statistics/VBM  
Group size and choice of method: 
 Larger groups are an advantage when studying PD since grey matter loss seems to be 
less than for AD patients. Very few studies had been published on this topic when we 
started, and one of the results of this work is that for these patients larger groups 
should be collected n > 30 or perhaps more. One of the reasons for this could be that 
PD patients are more heterogeneous both clinically and concerning brain atrophy than 
AD patients. Another possibility is that there is less annual brain atrophy, as has been 
shown by longitudinal studies156 and more sub cortical changes as has been shown 
pathologically.117 Larger groups are thus needed, which necessitates either multi-
centre studies or longer duration of data collection. 
Future research should compare different methods to evaluate grey matter 
loss/cortical atrophy. We chose VBM based on recommendations, and the availability 
of experienced users to guide us. It is free software, widely used for imaging studies, 
and only requires Matlab as a platform, which we could acquire at a low cost. Since 
then a lot of other imaging software has been used world wide by other investigators 
in the study of atrophy or regional changes in the brain.15, 189 Many of these methods 
are developed on campus and are not freely available to the imaging community, and 
others are quite expensive to purchase.  
Presentation of VBM results 
Modulation of images used for VBM was introduced with the paper by Good et al in 
2000.10 Before that studies using VBM were unmodulated images ie showing 
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differences in tissue concentration in structural MRI. Unmodulated results have been 
confirmed using a different imaging method for the same images e.g.190  
 Modulated images shows regional cerebral volume differences.10 Many papers only 
report modulated images in their results, others report both, and some report only un-
modulated results. The choice of which results to report is a matter of constant debate 
in the SPM e-mail list, where researchers post questions, and get answers and 
viewpoints from colleagues. (http://www.fil.ion.ucl.ac.uk/spm/support) Depending 
on who you ask, the answers may vary. In the papers of this thesis we mostly present 
unmodulated results. Future studies will have to resolve this question, maybe by 
neuropathologic confirmation of VBM findings or confirmation of results through 
other imaging approaches e.g. ROI analyses or other whole brain analyses.  
Presentation of uncorrected results 
In VBM several hundred thousand voxels may be included in the analysis of two 
independent groups. Therefore a number of false positive voxels will appear at a 
statistical threshold of p<0.001. To correct for this a Bonferroni correction could be 
performed, but since neighbouring voxels are not independent, but rather are highly 
correlated, the Bonferroni correction will be too conservative. (http://imaging.mrc-
cbu.cam.ac.uk/imaging/) In addition, analyses in VBM are done on smoothed images 
(so that they are normally distributed), which make the data in each voxel more 
correlated with the neighbouring voxels. In addition it is not possible to find out how 
many independent observations there are, therefore the Random Field theory is used 
to determine the Z-threshold in SPM. Two methods for correction of results exist 
within the SPM2 software package, family wise error (FWE) and false discovery rate 
(FDR). FWE is also considered to be a harsh method of correction, and little is 
published on the use of FDR for correction in VBM studies. There is a continuing 
debate about this. For future studies of dementia using VBM, providing that there are 
prior hypotheses about expected changes, uncorrected results can be published,191 but 
larger studies are recommended to possibly avoid this issue.  
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Method for the evaluation of WMH 
The method by Scheltens has been validated and used in several studies.35, 192 It has 
also been found to have significant agreement with quantitative volumetric 
measurement of age-related white matter changes,193 although a similar but smaller, 
study found the opposite.194 We chose to use it instead of more recent visual rating 
methods e.g.195 which has not become widely used even though they are argued to be 
better than the older ones.194 Automated methods have recently been developed for 
the evaluation of volume of lesions.196 Our images did not meet the requirements for 
use in these computerised methods mainly because our FLAIR images were coronal 
slices and the interslice gap was too big. 
The changes in white matter due to ageing have not been the focus of attention in the 
same way as grey matter changes. With the more widespread use of new imaging 
techniques like diffusion tensor imaging, I think this will change in the years to come. 
5.3 Results 
5.3.1 White-matter lesions 
We found an association with increased load of WMH in PDD compared to PD, 
which was a novel finding.  Increased WMH burden  has consistently been found to 
be associated with impaired cognition and mental slowing,197, 198 and with other types 
of dementia.35 Often, increased WMH are associated with cerebrovascular disease, 
but this is not found in PD. Our finding of a low level of WMH in PD is in line with 
previous research showing that risk factors for cerebrovascular disease are reduced in 
PD compared to controls.199 A previous record-based study from our group did not 
find that risk-factors for vascular disease were associated with dementia in PD.116  
Thus other mechanisms may   lead to increased WHM in patients with PDD e.g. 
hypotension or some other common mechanism associated with advanced disease. 
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The more severe changes found in PDD suggests however that in some patients, 
WMH may contribute to cognitive impairment.  
5.3.2 Atrophy 
Relationship of imaging findings and neuropathology in PD 
With whole brain analysis methods like VBM the regional tissue concentration 
differences throughout the brain can be compared between groups. Neuropathology 
studies can not work as detailed as this covering all brain regions. Therefore to 
directly compare atrophy in MRI with load or distribution of Lewy body pathology or 
Alzheimer pathology in the brain is difficult. This kind of comparison would work 
better in defined regions of interest of smaller structures, like the hippocampus.  Thus 
whole brain image analysis can indicate which brain regions that can be interesting to 
study with neuropathology. Additional advantages of imaging are the possibilities to 
study changes early in course and to follow patients longitudinally, whereas 
pathology is confined to end-stage disease.  
Relationship of atrophy to cognitive changes in PD 
Our grey matter findings are in line with other studies, supporting the hypothesis that 
morphological changes in the cortex contribute to dementia in PD.  The affected 
areas are previously shown to be involved in cognitive processes. We found grey 
matter structural changes associated with cognitive impairment in PD, thus cognitive 
impairment early in PD are not entirely based on functional changes. 
Cortical atrophy in PDD compared to DLB and AD 
The regional differences between PDD and AD are consistent with the reported 
clinical differences in cognitive profile with more executive dysfunction and 
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impaired attention in PDD and more memory impairment and problems with 
orientation in AD.200 
Differences found between DLB and PDD shed light on the ongoing discussion 
whether DLB and PDD are different diseases or represent stages on a continuum of 
Lewy body disease. Although clinical and pathological similarities exist, our findings 
are in line with several recent studies demonstrating different brain changes, which 
may relate to the subtle clinical differences reported in detailed studies.  
Clinical implications of findings 
Our findings provide new knowledge in understanding the relationship between 
cognitive impairment and brain changes in PD, and how these contrast with other 
related neurodegenerative disorders. Our results support the notion that cognitive 
impairment is a consequence of morphological brain changes of PD, rather than 
solely being the effect of long term medication, functional changes, or concomitant 
AD or vascular pathology. Due to a large inter-individual overlap, and time 
consuming analyses, current methods for the analysis of structural MRI can provide 
only limited information in the differential diagnosis of individual patients with 
dementia. Future studies with new and refined methods, will hopefully provide more 
diagnostic and prognostic information about the risk of future cognitive decline in 
patients with PD. 
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6. Conclusions 
The results of the studies included in this thesis, gives valuable new information 
about structural changes accompanying PD both in white matter and grey matter, and 
our results can give rise to new hypotheses for future imaging studies of PD. 
Challenges for future studies will be to design larger longitudinal studies which can 
follow the MRI brain changes in PD along with the clinical and cognitive functions. 
Another challenge will be to find out which symptoms of cognitive impairment that 
reliably can predict development of dementia, and to find the associated brain 
changes. 
 66 
7. References 
1. Rabi, II, Zacharias JR, Millman S, Kusch P. Milestones in magnetic resonance: 'a 
new method of measuring nuclear magnetic moment' . 1938. J Magn Reson Imaging 
1992;2:131-133. 
2. Lauterbur PC. Image formation by induced local interactions. Examples employing 
nuclear magnetic resonance. 1973. Clin Orthop Relat Res 1989:3-6. 
3. Mansfield P, Maudsley AA. Medical imaging by NMR. Br J Radiol 1977;50:188-
194. 
4. Myhr G, Nordlid K, Bjørnerud A, Galtung Lihaug E. Fokus på MRI og bruk av 
kontrastmidler. Oslo: Amersham Health AS; 2002. 
5. Stark DD, Bradley WGJ. Magnetic Resonance Imaging. third ed. St Louis, 
Missouri: Mosby; 1999. 
6. Chilton HM, Ekstrand KE. Principles and applications of nuclear magnetic 
resonance imaging. Am J Hosp Pharm 1984;41:763-768. 
7. Brant-Zawadzki M, Norman D. Magnetic Resonance Imaging of the Central 
Nervous System. New York: Raven Press Books Ltd.; 1987. 
8. Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. I. Segmentation and 
surface reconstruction. Neuroimage 1999;9:179-194. 
9. Salat DH, Buckner RL, Snyder AZ, et al. Thinning of the cerebral cortex in aging. 
Cereb Cortex 2004;14:721-730. 
10. Good CD, Johnsrude IS, Ashburner J, Henson RNA, Friston KJ, Frackowiak RSJ. A 
Voxel-Based Morphometric Study of Ageing in 465 Normal Adult Human Brains. 
NeuroImage 2001;14:21-36. 
11. Grieve SM, Clark CR, Williams LM, Peduto AJ, Gordon E. Preservation of limbic 
and paralimbic structures in aging. Hum Brain Mapp 2005;25:391-401. 
12. Raz N, Rodrigue KM, Kennedy KM, Head D, Gunning-Dixon F, Acker JD. 
Differential aging of the human striatum: longitudinal evidence. AJNR Am J 
Neuroradiol 2003;24:1849-1856. 
13. Sowell ER, Peterson BS, Kan E, et al. Sex Differences in Cortical Thickness 
Mapped in 176 Healthy Individuals between 7 and 87 Years of Age. Cereb Cortex 
2006. 
14. Scahill RI, Frost C, Jenkins R, Whitwell JL, Rossor MN, Fox NC. A longitudinal 
study of brain volume changes in normal aging using serial registered magnetic 
resonance imaging. Arch Neurol 2003;60:989-994. 
 67 
15. Fox NC, Crum WR, Scahill RI, Stevens JM, Janssen JC, Rossor MN. Imaging of 
onset and progression of Alzheimer's disease with voxel-compression mapping of 
serial magnetic resonance images. Lancet 2001;358:201-205. 
16. Paviour DC, Price SL, Jahanshahi M, Lees AJ, Fox NC. Longitudinal MRI in 
progressive supranuclear palsy and multiple system atrophy: rates and regions of 
atrophy. Brain 2006;129:1040-1049. 
17. Bartzokis G, Sultzer D, Lu PH, Nuechterlein KH, Mintz J, Cummings JL. 
Heterogeneous age-related breakdown of white matter structural integrity: 
implications for cortical "disconnection" in aging and Alzheimer's disease. 
Neurobiol Aging 2004;25:843-851. 
18. Salat DH, Tuch DS, Greve DN, et al. Age-related alterations in white matter 
microstructure measured by diffusion tensor imaging. Neurobiol Aging 
2005;26:1215-1227. 
19. Fazekas F, Kleinert R, Offenbacher H, et al. Pathologic correlates of incidental MRI 
white matter signal hyperintensities. Neurology 1993;43:1683-1689. 
20. Firbank MJ, Minett T, O'Brien JT. Changes in DWI and MRS associated with white 
matter hyperintensities in elderly subjects. Neurology 2003;61:950-954. 
21. Fernando MS, O'Brien JT, Perry RH, et al. Comparison of the pathology of cerebral 
white matter with post-mortem magnetic resonance imaging (MRI) in the elderly 
brain. Neuropathol Appl Neurobiol 2004;30:385-395. 
22. Fernando MS, Simpson JE, Matthews F, et al. White matter lesions in an unselected 
cohort of the elderly: molecular pathology suggests origin from chronic 
hypoperfusion injury. Stroke 2006;37:1391-1398. 
23. Jobst KA, Smith AD, Szatmari M, et al. Detection in life of confirmed Alzheimer's 
disease using a simple measurement of medial temporal lobe atrophy by computed 
tomography. Lancet 1992;340:1179-1183. 
24. Fox NC, Warrington EK, Freeborough PA, et al. Presymptomatic hippocampal 
atrophy in Alzheimer's disease. A longitudinal MRI study. Brain 1996;119 ( Pt 
6):2001-2007. 
25. Callen DJ, Black SE, Gao F, Caldwell CB, Szalai JP. Beyond the hippocampus: 
MRI volumetry confirms widespread limbic atrophy in AD. Neurology 
2001;57:1669-1674. 
26. Frisoni GB, Geroldi C, Beltramello A, et al. Radial Width of the Temporal Horn: A 
Sensitive Measure in Alzheimer Disease. Am J Neuroradiol 2002;23:35-47. 
27. Pennanen C, Kivipelto M, Tuomainen S, et al. Hippocampus and entorhinal cortex 
in mild cognitive impairment and early AD. Neurobiol Aging 2004;25:303-310. 
28. Pennanen C, Testa C, Laakso MP, et al. A voxel based morphometry study on mild 
cognitive impairment. J Neurol Neurosurg Psychiatry 2005;76:11-14. 
 68 
29. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia 
with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-
1872. 
30. Gao FQ, Black SE, Leibovitch FS, Callen DJ, Rockel CP, Szalai JP. Linear width of 
the medial temporal lobe can discriminate Alzheimer's disease from normal aging: 
the Sunnybrook dementia study. Neurobiol Aging 2004;25:441-448. 
31. Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG, O'Brien JT. Medial 
temporal lobe atrophy on MRI in dementia with Lewy bodies. Neurology 
1999;52:1153-1158. 
32. Cousins DA, Burton EJ, Burn D, Gholkar A, McKeith IG, O'Brien JT. Atrophy of 
the putamen in dementia with Lewy bodies but not Alzheimer's disease: an MRI 
study. Neurology 2003;61:1191-1195. 
33. Brenneis C, Wenning GK, Egger KE, et al. Basal forebrain atrophy is a distinctive 
pattern in dementia with Lewy bodies. Neuroreport 2004;15:1711-1714. 
34. Hanyu H, Shimizu S, Tanaka Y, Hirao K, Iwamoto T, Abe K. MR features of the 
substantia innominata and therapeutic implications in dementias. Neurobiol Aging 
2007;28:548-554. 
35. Barber R, Scheltens P, Gholkar A, et al. White matter lesions on magnetic resonance 
imaging in dementia with Lewy bodies, Alzheimer's disease, vascular dementia, and 
normal aging. J Neurol Neurosurg Psychiatry 1999;67:66-72. 
36. O'Brien JT, Paling S, Barber R, et al. Progressive Brain Atrophy on Serial MRI in 
Dementia with Lewy Bodies, AD and Vascular Dementia. Neurology 2001;56:1386-
1388. 
37. Whitwell JL, Weigand SD, Shiung MM, et al. Focal atrophy in dementia with Lewy 
bodies on MRI: a distinct pattern from Alzheimer's disease. Brain 2007;130:708-
719. 
38. Tandberg E, Larsen JP, Nessler EG, Riise T, Aarli JA. The epidemiology of 
Parkinson's disease in the county of Rogaland, Norway. Mov Disord 1995;10:541-
549. 
39. Porter B, Macfarlane R, Unwin N, Walker R. The prevalence of Parkinson's disease 
in an area of North Tyneside in the North-East of England. Neuroepidemiology 
2006;26:156-161. 
40. Schrag A, Ben-Shlomo Y, Quinn NP. Cross sectional prevalence survey of 
idiopathic Parkinson's disease and Parkinsonism in London. Bmj 2000;321:21-22. 
41. Mayeux R, Denaro J, Hemenegildo N, et al. A population-based investigation of 
Parkinson's disease with and without dementia. Relationship to age and gender. 
Arch Neurol 1992;49:492-497. 
 69 
42. de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM. 
Incidence of parkinsonism and Parkinson disease in a general population: the 
Rotterdam Study. Neurology 2004;63:1240-1244. 
43. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with 
Parkinson disease in the most populous nations, 2005 through 2030. Neurology 
2007;68:384-386. 
44. Zhang ZX, Roman GC. Worldwide occurrence of Parkinson's disease: an updated 
review. Neuroepidemiology 1993;12:195-208. 
45. Nicoletti A, Sofia V, Bartoloni A, et al. Prevalence of Parkinson's disease: a door-to-
door survey in rural Bolivia. Parkinsonism Relat Disord 2003;10:19-21. 
46. Barbosa MT, Caramelli P, Maia DP, et al. Parkinsonism and Parkinson's disease in 
the elderly: a community-based survey in Brazil (the Bambui study). Mov Disord 
2006;21:800-808. 
47. Zhang ZX, Roman GC, Hong Z, et al. Parkinson's disease in China: prevalence in 
Beijing, Xian, and Shanghai. Lancet 2005;365:595-597. 
48. Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson's 
disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 
2003;157:1015-1022. 
49. Sellbach AN, Boyle RS, Silburn PA, Mellick GD. Parkinson's disease and family 
history. Parkinsonism Relat Disord 2006;12:399-409. 
50. Gorell JM, Peterson EL, Rybicki BA, Johnson CC. Multiple risk factors for 
Parkinson's disease. J Neurol Sci 2004;217:169-174. 
51. Farrer MJ. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat 
Rev Genet 2006;7:306-318. 
52. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. 
Alpha-synuclein in Lewy bodies. Nature 1997;388:839-840. 
53. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein 
gene identified in families with Parkinson's disease. Science 1997;276:2045-2047. 
54. Benmoyal-Segal L, Soreq H. Gene-environment interactions in sporadic Parkinson's 
disease. J Neurochem 2006;97:1740-1755. 
55. Abbott RD, Ross GW, White LR, et al. Midlife adiposity and the future risk of 
Parkinson's disease. Neurology 2002;59:1051-1057. 
56. Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the 
future risk of Parkinson's disease. Neurology 2001;57:456-462. 
57. Popat RA, Van Den Eeden SK, Tanner CM, et al. Effect of reproductive factors and 
postmenopausal hormone use on the risk of Parkinson disease. Neurology 
2005;65:383-390. 
 70 
58. Wright JM, Keller-Byrne J. Environmental determinants of Parkinson's disease. 
Arch Environ Occup Health 2005;60:32-38. 
59. Kamel F, Tanner C, Umbach D, et al. Pesticide Exposure and Self-reported 
Parkinson's Disease in the Agricultural Health Study. Am J Epidemiol 
2007;165:364-374. 
60. Petrovitch H, Ross GW, Abbott RD, et al. Plantation work and risk of Parkinson 
disease in a population-based longitudinal study. Arch Neurol 2002;59:1787-1792. 
61. Priyadarshi A, Khuder SA, Schaub EA, Priyadarshi SS. Environmental risk factors 
and Parkinson's disease: a metaanalysis. Environ Res 2001;86:122-127. 
62. Lai BC, Marion SA, Teschke K, Tsui JK. Occupational and environmental risk 
factors for Parkinson's disease. Parkinsonism Relat Disord 2002;8:297-309. 
63. Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ. A meta-analysis of 
coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 
2002;52:276-284. 
64. Alves G, Kurz M, Lie SA, Larsen JP. Cigarette smoking in Parkinson's disease: 
influence on disease progression. Mov Disord 2004;19:1087-1092. 
65. Trojanowski JQ, Lee VM. Aggregation of neurofilament and alpha-synuclein 
proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and 
Lewy body dementia. Arch Neurol 1998;55:151-152. 
66. Braak H, Sandmann-Keil D, Gai W, Braak E. Extensive axonal Lewy neurites in 
Parkinson's disease: a novel pathological feature revealed by alpha-synuclein 
immunocytochemistry. Neurosci Lett 1999;265:67-69. 
67. Braak H, Bohl JR, Muller CM, Rub U, de Vos RA, Del Tredici K. Stanley Fahn 
Lecture 2005: The staging procedure for the inclusion body pathology associated 
with sporadic Parkinson's disease reconsidered. Mov Disord 2006;21:2042-2051. 
68. Spillantini MG, Goedert M. The alpha-synucleinopathies: Parkinson's disease, 
dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci 
2000;920:16-27. 
69. Braak H, Rub U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible 
routes by which vulnerable neuronal types may be subject to neuroinvasion by an 
unknown pathogen. J Neural Transm 2003;110:517-536. 
70. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the 
striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and 
clinical implications. N Engl J Med 1988;318:876-880. 
71. Morrish PK, Sawle GV, Brooks DJ. Clinical and [18F] dopa PET findings in early 
Parkinson's disease. J Neurol Neurosurg Psychiatry 1995;59:597-600. 
 71 
72. Perry EK, McKeith I, Thompson P, et al. Topography, extent, and clinical relevance 
of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and 
Alzheimer's disease. Ann N Y Acad Sci 1991;640:197-202. 
73. Tiraboschi P, Hansen LA, Alford M, et al. Cholinergic dysfunction in diseases with 
Lewy bodies. Neurology 2000;54:407-411. 
74. Rinne JO, Myllykyla T, Lonnberg P, Marjamaki P. A postmortem study of brain 
nicotinic receptors in Parkinson's and Alzheimer's disease. Brain Res 1991;547:167-
170. 
75. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 
1999;56:33-39. 
76. Quinn N. Parkinsonism--recognition and differential diagnosis. Bmj 1995;310:447-
452. 
77. Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med 
1998;339:1044-1053. 
78. Larsen JP, Dupont E, Tandberg E. Clinical diagnosis of Parkinson's disease. 
Proposal of diagnostic subgroups classified at different levels of confidence. Acta 
Neurol Scand 1994;89:242-251. 
79. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of 
idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol 
Neurosurg Psychiatry 1992;55:181-184. 
80. Schrag A, Ben-Shlomo Y, Quinn N. How valid is the clinical diagnosis of 
Parkinson's disease in the community? J Neurol Neurosurg Psychiatry 2002;73:529-
534. 
81. Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with 
newly diagnosed Parkinson disease. Neurology 2005;65:1239-1245. 
82. Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an 
incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 
2004;127:550-560. 
83. Emre M. What causes mental dysfunction in Parkinson's disease? Mov Disord 
2003;18 Suppl 6:S63-71. 
84. Lewis SJ, Dove A, Robbins TW, Barker RA, Owen AM. Cognitive impairments in 
early Parkinson's disease are accompanied by reductions in activity in frontostriatal 
neural circuitry. J Neurosci 2003;23:6351-6356. 
85. Mattay VS, Tessitore A, Callicott JH, et al. Dopaminergic modulation of cortical 
function in patients with Parkinson's disease. Ann Neurol 2002;51:156-164. 
86. Rinne JO, Portin R, Ruottinen H, et al. Cognitive impairment and the brain 
dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission 
tomographic study. Arch Neurol 2000;57:470-475. 
 72 
87. Graham JE, Rockwood K, Beattie BL, et al. Prevalence and severity of cognitive 
impairment with and without dementia in an elderly population. Lancet 
1997;349:1793-1796. 
88. Gauthier S, Reisberg B, Zaudig M, et al. Mild cognitive impairment. Lancet 
2006;367:1262-1270. 
89. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Kokmen E, Tangelos EG. Aging, 
memory, and mild cognitive impairment. Int Psychogeriatr 1997;9 Suppl 1:65-69. 
90. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive 
impairment. Arch Neurol 2001;58:1985-1992. 
91. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 
2004;256:183-194. 
92. Janvin C, Aarsland D, Larsen JP, Hugdahl K. Neuropsychological profile of patients 
with Parkinson's disease without dementia. Dement Geriatr Cogn Disord 
2003;15:126-131. 
93. Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive 
impairment in Parkinson's disease: progression to dementia. Mov Disord 
2006;21:1343-1349. 
94. Hughes TA, Ross HF, Musa S, et al. A 10-year study of the incidence of and factors 
predicting dementia in Parkinson's disease. Neurology 2000;54:1596-1602. 
95. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P. Risk of 
dementia in Parkinson's disease: a community-based, prospective study. Neurology 
2001;56:730-736. 
96. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of 
dementia in Parkinson's disease. Mov Disord 2005;20:1255-1263. 
97. Galvin JE, Pollack J, Morris JC. Clinical phenotype of Parkinson disease dementia. 
Neurology 2006;67:1605-1611. 
98. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and 
characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch 
Neurol 2003;60:387-392. 
99. Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D. Changes in motor 
subtype and risk for incident dementia in Parkinson's disease. Mov Disord 
2006;21:1123-1130. 
100. Aarsland D, Kvaloy JT, Andersen K, et al. The effect of age of onset of PD on risk 
of dementia. Journal of Neurology 2007;254:38-45. 
101. Aarsland D, Bronnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with 
PD and dementia: Frequency, profile and associated caregiver stress. J Neurol 
Neurosurg Psychiatry 2006. 
 73 
102. Rippon GA, Marder KS. Dementia in Parkinson's disease. Adv Neurol 2005;96:95-
113. 
103. American PA. Diagnostic and Statistical Manual of Mental Disorders, DSM IV. 
Fourth edition ed; 1996. 
104. Aarsland D, Litvan I, Salmon D, Galasko D, Wentzel-Larsen T, Larsen JP. 
Performance on the dementia rating scale in Parkinson's disease with dementia and 
dementia with Lewy bodies: comparison with progressive supranuclear palsy and 
Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003;74:1215-1220. 
105. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia 
associated with Parkinson disease. Movement Disorders 2007. 
106. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003;2:229-
237. 
107. Hurtig HI, Trojanowski JQ, Galvin J, et al. Alpha-synuclein cortical Lewy bodies 
correlate with dementia in Parkinson's disease. Neurology 2000;54:1916-1921. 
108. Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA. Cognitive status 
correlates with neuropathologic stage in Parkinson disease. Neurology 
2005;64:1404-1410. 
109. Aarsland D, Perry R, Brown A, Larsen JP, Ballard C. Neuropathology of dementia 
in Parkinson's disease: A prospective, community-based study. Ann Neurol 
2005;58:773-776. 
110. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW. Parkinson disease 
neuropathology: later-developing dementia and loss of the levodopa response. 
Archives of Neurology 2002;59:102-112. 
111. Aarsland D, Ballard CG, Halliday G. Are Parkinson's disease with dementia and 
dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol 
2004;17:137-145. 
112. Colosimo C, Hughes AJ, Kilford L, Lees AJ. Lewy body cortical involvement may 
not always predict dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 
2003;74:852-856. 
113. Jellinger KA. Recent developments in the pathology of Parkinson's disease. J Neural 
Transm Suppl 2002:347-376. 
114. Tsuboi Y, Dickson DW. Dementia with Lewy bodies and Parkinson's disease with 
dementia: are they different? Parkinsonism Relat Disord 2005;11 Suppl 1:S47-51. 
115. Jellinger KA. Prevalence of cerebrovascular lesions in Parkinson's disease. A 
postmortem study. Acta Neuropathol (Berl) 2003;105:415-419. 
116. Haugarvoll K, Aarsland D, Wentzel-Larsen T, Larsen JP. The influence of 
cerebrovascular risk factors on incident dementia in patients with Parkinson's 
disease. Acta Neurol Scand 2005;112:386-390. 
 74 
117. Ballard C, Ziabreva I, Perry R, et al. Differences in neuropathologic characteristics 
across the Lewy body dementia spectrum. Neurology 2006;67:1931-1934. 
118. Perry EK, Curtis M, Dick DJ, et al. Cholinergic correlates of cognitive impairment 
in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg 
Psychiatry 1985;48:413-421. 
119. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more 
severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo 
positron emission tomographic study. Arch Neurol 2003;60:1745-1748. 
120. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and 
pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium 
on DLB international workshop. Neurology 1996;47:1113-1124. 
121. McKeith I, Mintzer J, Aarsland D, et al. Dementia with Lewy bodies. Lancet Neurol 
2004;3:19-28. 
122. Hohl U, Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J. Diagnostic accuracy of 
dementia with Lewy bodies. Arch Neurol 2000;57:347-351. 
123. Litvan I, MacIntyre A, Goetz CG, et al. Accuracy of the clinical diagnoses of Lewy 
body disease, Parkinson disease, and dementia with Lewy bodies: a 
clinicopathologic study. Arch Neurol 1998;55:969-978. 
124. McKeith I, O'Brien J, Walker Z, et al. Sensitivity and specificity of dopamine 
transporter imaging with (123)I-FP-CIT SPECT in dementia with Lewy bodies: a 
phase III, multicentre study. Lancet Neurol 2007;6:305-313. 
125. Emre M. Dementia in Parkinson's disease: cause and treatment. Curr Opin Neurol 
2004;17:399-404. 
126. Kukull WA, Higdon R, Bowen JD, et al. Dementia and Alzheimer disease 
incidence: a prospective cohort study. Arch Neurol 2002;59:1737-1746. 
127. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta 
Neuropathol (Berl) 1991;82:239-259. 
128. Thal DR, Capetillo-Zarate E, Del Tredici K, Braak H. The development of amyloid 
beta protein deposits in the aged brain. Sci Aging Knowledge Environ 
2006;2006:re1. 
129. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical 
diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group 
under the auspices of Department of Health and Human Services Task Force on 
Alzheimer's Disease. Neurology 1984;34:939-944. 
130. Kukull WA, Larson EB, Reifler BV, Lampe TH, Yerby MS, Hughes JP. The 
validity of 3 clinical diagnostic criteria for Alzheimer's disease. Neurology 
1990;40:1364-1369. 
 75 
131. Bhattacharya K, Saadia D, Eisenkraft B, et al. Brain magnetic resonance imaging in 
multiple-system atrophy and Parkinson disease: a diagnostic algorithm. Arch Neurol 
2002;59:835-842. 
132. Nicoletti G, Fera F, Condino F, et al. MR imaging of middle cerebellar peduncle 
width: differentiation of multiple system atrophy from Parkinson disease. Radiology 
2006;239:825-830. 
133. Sasaki M, Shibata E, Tohyama K, et al. Neuromelanin magnetic resonance imaging 
of locus ceruleus and substantia nigra in Parkinson's disease. Neuroreport 
2006;17:1215-1218. 
134. Scherfler C, Schocke MF, Seppi K, et al. Voxel-wise analysis of diffusion weighted 
imaging reveals disruption of the olfactory tract in Parkinson's disease. Brain 
2006;129:538-542. 
135. Sawada H, Udaka F, Kameyama M, et al. SPECT findings in Parkinson's disease 
associated with dementia. J Neurol Neurosurg Psychiatry 1992;55:960-963. 
136. Spampinato U, Habert MO, Mas JL, et al. (99mTc)-HM-PAO SPECT and cognitive 
impairment in Parkinson's disease: a comparison with dementia of the Alzheimer 
type. J Neurol Neurosurg Psychiatry 1991;54:787-792. 
137. Antonini A, De Notaris R, Benti R, De Gaspari D, Pezzoli G. Perfusion 
ECD/SPECT in the characterization of cognitive deficits in Parkinson's disease. 
Neurol Sci 2001;22:45-46. 
138. Osaki Y, Morita Y, Fukumoto M, Akagi N, Yoshida S, Doi Y. Three-dimensional 
stereotactic surface projection SPECT analysis in Parkinson's disease with and 
without dementia. Mov Disord 2005;20:999-1005. 
139. Innis RB, Seibyl JP, Scanley BE, et al. Single photon emission computed 
tomographic imaging demonstrates loss of striatal dopamine transporters in 
Parkinson disease. Proc Natl Acad Sci U S A 1993;90:11965-11969. 
140. Poewe W, Scherfler C. Role of dopamine transporter imaging in investigation of 
parkinsonian syndromes in routine clinical practice. Mov Disord 2003;18 Suppl 
7:S16-21. 
141. O'Brien JT, Colloby S, Fenwick J, et al. Dopamine transporter loss visualized with 
FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch 
Neurol 2004;61:919-925. 
142. Scherfler C, Seppi K, Donnemiller E, et al. Voxel-wise analysis of [123I]beta-CIT 
SPECT differentiates the Parkinson variant of multiple system atrophy from 
idiopathic Parkinson's disease. Brain 2005;128:1605-1612. 
143. Taki J, Nakajima K, Hwang EH, et al. Peripheral sympathetic dysfunction in 
patients with Parkinson's disease without autonomic failure is heart selective and 
disease specific. taki@med.kanazawa-u.ac.jp. Eur J Nucl Med 2000;27:566-573. 
 76 
144. Hanyu H, Shimizu S, Hirao K, et al. The role of 123I-metaiodobenzylguanidine 
myocardial scintigraphy in the diagnosis of Lewy body disease in patients with 
dementia in a memory clinic. Dement Geriatr Cogn Disord 2006;22:379-384. 
145. Huber SJ, Shuttleworth EC, Christy JA, Chakeres DW, Curtin A, Paulson GW. 
Magnetic resonance imaging in dementia of Parkinson's disease. J Neurol Neurosurg 
Psychiatry 1989;52:1221-1227. 
146. Laakso MP, Partanen K, Riekkinen P, et al. Hippocampal volumes in Alzheimer's 
disease, Parkinson's disease with and without dementia, and in vascular dementia: 
An MRI study. Neurology 1996;46:678-681. 
147. Junque C, Ramirez-Ruiz B, Tolosa E, et al. Amygdalar and hippocampal MRI 
volumetric reductions in Parkinson's disease with dementia. Mov Disord 
2005;20:540-544. 
148. Tam CW, Burton EJ, McKeith IG, Burn DJ, O'Brien JT. Temporal lobe atrophy on 
MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and 
dementia with Lewy bodies. Neurology 2005;64:861-865. 
149. Camicioli R, Moore MM, Kinney A, Corbridge E, Glassberg K, Kaye JA. 
Parkinson's disease is associated with hippocampal atrophy. Mov Disord 
2003;18:784-790. 
150. Bruck A, Kurki T, Kaasinen V, Vahlberg T, Rinne JO. Hippocampal and prefrontal 
atrophy in patients with early non-demented Parkinson's disease is related to 
cognitive impairment. J Neurol Neurosurg Psychiatry 2004;75:1467-1469. 
151. Almeida OP, Burton EJ, McKeith I, Gholkar A, Burn D, O'Brien JT. MRI study of 
caudate nucleus volume in Parkinson's disease with and without dementia with 
Lewy bodies and Alzheimer's disease. Dement Geriatr Cogn Disord 2003;16:57-63. 
152. Burton EJ, McKeith IG, Burn DJ, Williams ED, O' Brien JT. Cerebral atrophy in 
Parkinson's disease with and without dementia: a comparison with Alzheimer's 
disease, dementia with Lewy bodies and controls. Brain 2004;127:791-800. 
153. Nagano-Saito A, Washimi Y, Arahata Y, et al. Cerebral atrophy and its relation to 
cognitive impairment in Parkinson disease. Neurology 2005;64:224-229. 
154. Summerfield C, Junque C, Tolosa E, et al. Structural brain changes in Parkinson 
disease with dementia: a voxel-based morphometry study. Arch Neurol 
2005;62:281-285. 
155. Hu MT, White SJ, Chaudhuri KR, Morris RG, Bydder GM, Brooks DJ. Correlating 
rates of cerebral atrophy in Parkinson's disease with measures of cognitive decline. J 
Neural Transm 2001;108:571-580. 
156. Burton EJ, McKeith IG, Burn DJ, O'Brien JT. Brain atrophy rates in Parkinson's 
disease with and without dementia using serial magnetic resonance imaging. Mov 
Disord 2005;20:1571-1576. 
 77 
157. Chan D, Janssen JC, Whitwell JL, et al. Change in rates of cerebral atrophy over 
time in early-onset Alzheimer's disease: longitudinal MRI study. Lancet 
2003;362:1121-1122. 
158. Ramirez-Ruiz B, Marti MJ, Tolosa E, et al. Longitudinal evaluation of cerebral 
morphological changes in Parkinson's disease with and without dementia. J Neurol 
2005;252:1345-1352. 
159. Burton EJ, McKeith IG, Burn DJ, Firbank MJ, O'Brien JT. Progression of white 
matter hyperintensities in Alzheimer disease, dementia with lewy bodies, and 
Parkinson disease dementia: a comparison with normal aging. Am J Geriatr 
Psychiatry 2006;14:842-849. 
160. Folstein MF, Folstein SE, Mc Hugh PR. " Mini - mental State ." A practical method 
for grading the mental state of patients for the clinician. J Psychiatr Res 1975;12:189 
-198. 
161. American PA. Diagnostic and Statistical Manual of Mental Disorders (DSM III). 
Washington DC; 1987. 
162. Mattis S. Dementia Rating Scale. New York: Grune & Stratton; 1976. 
163. Roth M, Tym E, Mountjoy CQ, et al. CAMDEX. A standardised instrument for the 
diagnosis of mental disorder in the elderly with special reference to the early 
detection of dementia. Br J Psychiatry 1986;149:698-709. 
164. Fahn S, Elton R, Committee MotUD. Unified Parkinson's disease Rating Scale. 
Florham Park, NJ: Macmillan Health Care Information; 1987. 
165. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 
1967;17:427-442. 
166. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. 
The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in 
dementia. Neurology 1994;44:2308-2314. 
167. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to 
change. Br J Psychiatry 1979;134:382-389. 
168. Benton AL. The revised visual retention test. 4th edition ed. New York: 
Psychological corporation.; 1974. 
169. Benton AL, Varney NR, Hamsher KD. Visuospatial judgment. A clinical test. Arch 
Neurol 1978;35:364-367. 
170. Golden. Stroop color and word test. Chicago, IL: Stoelting; 1978. 
171. Scheltens P, Barkhof F, Leys D, et al. A semiquantative rating scale for the 
assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci 
1993;114:7-12. 
 78 
172. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal 
abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J 
Roentgenol 1987;149:351-356. 
173. Fleiss J. The design and analysis of clinical experiments. New York: Wiley; 1986. 
174. Ashburner J, Friston KJ. Voxel-based morphometry-the methods. Neuroimage 
2000:805-821. 
175. Wright IC, McGuire PK, Poline JB, et al. A voxel-based method for the statistical 
analysis of gray and white matter density applied to schizophrenia. Neuroimage 
1995;2:244-252. 
176. Frackowiak RS, Ashburner J, Penny WD, et al. Human Brain Function. London: 
Elsevier Academic Press; 2004. 
177. Talairach J, Tournoux P. Co-Planar Stereotaxic Atlas of the Human Brain. 3-
Dimensional Proportional System: An Approach to Cerebral Imaging. Stuttgart  
New York: Thieme Medical Publishers, Inc. New York; 1988. 
178. Lancaster JL, Woldorff MG, Parsons LM, et al. Automated Talairach atlas labels for 
functional brain mapping. Hum Brain Mapp 2000;10:120-131. 
179. Burton EJ, Karas G, Paling S, et al. Patterns of Cerebral Atrophy in Dementia with 
Lewy Bodies Using Voxel-Based Morphometry. NeuroImage 2002;17:618-630. 
180. Brett M, Leff AP, Rorden C, Ashburner J. Spatial normalization of brain images 
with focal lesions using cost function masking. Neuroimage 2001;14:486-500. 
181. Xu J, Kobayashi S, Yamaguchi S, Iijima K, Okada K, Yamashita K. Gender effects 
on age-related changes in brain structure. AJNR Am J Neuroradiol 2000;21:112-
118. 
182. Hanyu H, Shimizu S, Tanaka Y, Takasaki M, Koizumi K, Abe K. Differences in 
regional cerebral blood flow patterns in male versus female patients with Alzheimer 
disease. AJNR Am J Neuroradiol 2004;25:1199-1204. 
183. Kidron D, Black SE, Stanchev P, et al. Quantitative MR volumetry in Alzheimer's 
disease. Topographic markers and the effects of sex and education. Neurology 
1997;49:1504-1512. 
184. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of 
parkinsonian syndromes in a specialist movement disorder service. Brain 
2002;125:861-870. 
185. Lim A, Tsuang D, Kukull W, et al. Clinico-neuropathological correlation of 
Alzheimer's disease in a community-based case series. J Am Geriatr Soc 
1999;47:564-569. 
186. Geser F, Wenning GK, Poewe W, McKeith I. How to diagnose dementia with Lewy 
bodies: state of the art. Mov Disord 2005;20 Suppl 12:S11-20. 
 79 
187. O'Brien JT, Firbank MJ, Mosimann UP, Burn DJ, McKeith IG. Change in perfusion, 
hallucinations and fluctuations in consciousness in dementia with Lewy bodies. 
Psychiatry Res 2005;139:79-88. 
188. Aarsland D, Andersen K, Larsen JP, et al. The rate of cognitive decline in Parkinson 
disease. Arch Neurol 2004;61:1906-1911. 
189. Apostolova LG, Dinov ID, Dutton RA, et al. 3D comparison of hippocampal 
atrophy in amnestic mild cognitive impairment and Alzheimer's disease. Brain 
2006;129:2867-2873. 
190. Kubicki M, Shenton ME, Salisbury DF, et al. Voxel-based morphometric analysis of 
gray matter in first episode schizophrenia. Neuroimage 2002;17:1711-1719. 
191. Friston KJ, Holmes A, Poline JB, Price CJ, Frith CD. Detecting activations in PET 
and fMRI: levels of inference and power. Neuroimage 1996;4:223-235. 
192. O'Brien J, Perry R, Barber R, Gholkar A, Thomas A. The association between white 
matter lesions on magnetic resonance imaging and noncognitive symptoms. Ann N 
Y Acad Sci 2000;903:482-489. 
193. Kapeller P, Barber R, Vermeulen RJ, et al. Visual rating of age-related white matter 
changes on magnetic resonance imaging: scale comparison, interrater agreement, 
and correlations with quantitative measurements. Stroke 2003;34:441-445. 
194. Prins ND, van Straaten EC, van Dijk EJ, et al. Measuring progression of cerebral 
white matter lesions on MRI: visual rating and volumetrics. Neurology 
2004;62:1533-1539. 
195. de Leeuw FE, de Groot JC, Achten E, et al. Prevalence of cerebral white matter 
lesions in elderly people: a population based magnetic resonance imaging study. The 
Rotterdam Scan Study. J Neurol Neurosurg Psychiatry 2001;70:9-14. 
196. Burton EJ, Kenny RA, O'Brien J, et al. White matter hyperintensities are associated 
with impairment of memory, attention, and global cognitive performance in older 
stroke patients. Stroke 2004;35:1270-1275. 
197. Garde E, Mortensen EL, Krabbe K, Rostrup E, Larsson HB. Relation between age-
related decline in intelligence and cerebral white-matter hyperintensities in healthy 
octogenarians: a longitudinal study. Lancet 2000;356:628-634. 
198. De Groot JC, De Leeuw FE, Oudkerk M, et al. Periventricular cerebral white matter 
lesions predict rate of cognitive decline. Ann Neurol 2002;52:335-341. 
199. Scigliano G, Musicco M, Soliveri P, Piccolo I, Ronchetti G, Girotti F. Reduced risk 
factors for vascular disorders in Parkinson disease patients: a case-control study. 
Stroke 2006;37:1184-1188. 
200. Bronnick K, Emre M, Lane R, Tekin S, Aarsland D. Profile of cognitive impairment 
in dementia associated with Parkinson's disease compared to Alzheimer disease. J 
Neurol Neurosurg Psychiatry 2007. 
 80 
 
 81 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Paper I 

Movement Disorders  21(2), Beyer, M. K.; Aarsland, D.; Greve, O. J.; Larsen, J. P., Visual 
rating of white matter hyperintensities in Parkinson's disease, pp.  223-9. Copyright © 2005 
Movement Disorders Society Published by John Wiley & Sons, Ltd. Abstract only. Full-text 
not available due to publisher restrictions. http://dx.doi.org/10.1002/mds.20704       
 
Visual Rating of White Matter Hyperintensities in Parkinson’s Disease 
Mona K. Beyer, MD,1²* Dag Aarsland, MD, PhD,2 Ole Jacob Greve, MD,1 and Jan P. Larsen, MD, 
PhD3 
 
1Department of Radiology, Stavanger University Hospital, Stavanger, Norway 
2Department of Geriatric Psychiatry, Stavanger University Hospital, Stavanger, Norway 
3Department of Neurology, Stavanger University Hospital, Stavanger, Norway  
 
Abstract 
 
Dementia is a common complication of Parkinson’s disease (PD), but the cause is 
incompletely understood. In previous studies, dementia has been associated with an increase 
in hyperintense lesions in the cerebral white matter. The aim of this study was to explore 
whether white matter hyperintensities (WMH) on cerebral magnetic resonance imaging (MRI) 
are associated with dementia in PD. For this study, 35 patients with PD, 16 with dementia 
(PDD) and 19 without (PDND), and 20 control subjects were recruited. MRI scans of patients 
and controls were rated for WMH, blind to diagnosis, using the Scheltens visual rating scale. 
Both bivariate and multivariate statistical analyses were carried out. Cerebrovascular risk 
factors, education, gender, or age were similar across groups. Compared with the PDND 
group, the PDD group had significantly higher level of WMH in the deep white matter and 
in the periventricular areas. WMH in the deep white matter was the only variable that was 
associated significantly with Mini-Mental State Examination score and explained 38% of 
the variance in the multivariate linear regression analysis. Our findings suggest that WMH in 
the deep white matter may contribute to dementia in PD.  
 
Key words: Parkinson’s disease; dementia; MRI; white matter hyperintensity; cerebrovascular 
risk factor; visual rating 
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Background: Dementia is common in Parkinson’s disease, but the underlying brain pathology is not yet fully
understood.
Aim: To examine the changes in the brain of patients with Parkinson’s disease with mild cognitive impairment
(MCI) and dementia, using structural magnetic resonance imaging.
Methods: Using voxel-based morphometry, the grey matter atrophy on brain images of patients with
Parkinson’s disease and dementia (PDD; n = 16) and Parkinson’s disease without dementia (PDND; n = 20),
and healthy elderly subjects (n = 20) was studied. In the PDND group, 12 subjects had normal cognitive status
and 8 had MCI. Standardised rating scales for motor, cognitive and psychiatric symptoms were used.
Results: Widespread areas of cortical atrophy were found in patients with PDD compared with normal
controls (in both temporal and frontal lobes and in the left parietal lobe). Grey matter reductions were found
in frontal, parietal, limbic and temporal lobes in patients with PDD compared with those with PDND. In
patients with PDND with MCI, areas of reduced grey matter in the left frontal and both temporal lobes were
found.
Conclusion: These findings show that dementia in Parkinson’s disease is associated with structural neocortical
changes in the brain, and that cognitive impairment in patients with PDND may be associated with structural
changes in the brain. Further studies with larger groups of patients are needed to confirm these findings.
C
ognitive impairment and neuropsychiatric symptoms are
common in patients with Parkinson’s disease, and most
patients with Parkinson’s disease who survive .10 years
after the onset of Parkinson’s disease will eventually develop
dementia (PDD).1 The dementia profile of PDD is characterised
by executive, visuospatial and attentional impairment, suggest-
ing that frontostriatal changes are the main causes of dementia
in patients with Parkinson’s disease.2 3 In addition, a sub-
stantial proportion of patients with Parkinson’s disease have
mild cognitive impairment (MCI) without fulfilling dementia
criteria, even early in the course of disease.4 5 Preliminary
evidence suggests that these mild cognitive changes represent
the early stages of dementia.6 7
The few existing studies of Parkinson’s disease using
structural magnetic resonance imaging (MRI) techniques have
not consistently shown a specific pattern of atrophy in patients
with PDD. In a study measuring hippocampal volumes,8
patients with Parkinson’s disease with and without cognitive
impairment had more hippocampal atrophy than healthy age-
matched controls. Another volumetric study found reduction in
volume of both hippocampus and amygdala in patients with
PDD and patients with Parkinson’s disease without dementia
(PDND) compared with normal controls.9 These findings were
confirmed in a recent study using visual rating of the medial
temporal lobes. There were no significant differences in
hippocampal atrophy in patients with PDD compared with
those with PDND.10 Patients belonging to both Parkinson’s
disease groups, however, showed more hippocampal atrophy
than the control group.
In a study using voxel-based morphometry (VBM), neocor-
tical atrophy has also been reported in patients with PDD. VBM
is an automated, unbiased method for voxel-wise comparison
of anatomical data from high-resolution MRI. The method is
fairly new, introduced in 2000,11 and compares the density of
grey or white matter between groups of individuals. In patients
with PDD, reduced grey matter volume in temporal and
occipital lobes, right frontal and left parietal lobes were found,
together with subcortical areas.12 Similar but less widespread
atrophy was reported in a recent study, which also found
hippocampal atrophy in patients with PDD.13
Changes in MRI have also been reported in patients with
PDND using VBM. Reduced volumes in the right frontal lobe,12
temporal lobe and hippocampus,13 and limbic and parahippo-
campal atrophy have been found.14
Two longitudinal studies have recently been published on the
rates of atrophy in patients with Parkinson’s disease versus
controls. Whole-brain atrophy rates were significantly
increased in patients with PDD compared with those with
PDND and controls.15 No increase in atrophy in patients with
PDND compared with normal controls was found. Another
longitudinal study using VBM found progressive decreases in
the grey matter volume in limbic, paralimbic and temporo-
Abbreviations: ANCOVA, analysis of covariance; ANOVA, analysis of
variance; FWE, family-wise error; MCI, mild cognitive impairment; MMSE,
Mini-Mental State Examination; MRI, magnetic resonance imaging; PDD,
Parkinson’s disease with dementia; PDND, Parkinson’s disease without
dementia; SPM, statistical parametric mapping; SVC, small volume
correction; VBM, voxel-based morphometry
254
www.jnnp.com
occipital regions in patients with PDND, and, neocortical grey
matter loss was found in patients with PDD.16
No MRI studies of patients with Parkinson’s disease and MCI
have, to our knowledge, yet been reported. Thus, whether
structural changes exist in patients with Parkinson’s disease
and MCI, and whether the previously reported cortical and
hippocampal atrophy is present in all patients with PDND or
only in a subgroup with MCI is not clear.
To explore these issues, we investigated structural brain
MRIs of patients with Parkinson’s disease with and without
MCI and dementia and healthy elderly volunteers using VBM.
We hypothesised that patients with PDD would have more
pronounced cortical atrophy than controls and patients with
PDND, and that those with Parkinson’s disease with MCI
would show more atrophy than those with Parkinson’s disease
with intact cognition. On the basis of the cognitive profile of
PDD and previous MRI studies, we further hypothesised that
these changes in the brain would involve frontal, limbic and
temporal lobes, including the medial temporal cortex.
PATIENTS AND METHODS
Case-finding and diagnostic procedures
The patients were recruited from an ongoing epidemiological
study (sample 1).17 In addition, consecutive patients referred to
outpatient clinics of the Department of Neurology or the
Department of Geriatric Psychiatry, Stavanger University
Hospital, Stavanger, Norway, were included (sample 2). A
diagnosis of Parkinson’s disease was made by a neurologist,
according to explicit criteria.18 The minimum requirement for a
diagnosis of Parkinson’s disease was at least two of the cardinal
signs (akinesia, rigidity, resting tremor or postural abnormal-
ities) and a moderate response to a dopaminergic agent.
Staging of Parkinson’s disease was carried out according to
the Hoehn and Yahr scale.19 Sample 1 has been followed up
prospectively with a 4-year interval in 1993, 1997 and 2001 and
then assessed annually. The autopsy diagnosis in the first 22
patients, 2 of whom participated in the current MRI study, was
consistent with a diagnosis of Lewy-body Parkinson’s disease.20
Diagnosis of dementia
The diagnosis of dementia was based on a semistructured
interview with the patient and a care giver following the
Diagnostic and Statistical Manual of Mental Disorders-III-R
criteria for dementia21 (sample 1) or Diagnostic and Statistical
Manual of Mental Disorders IV (sample 2).22 All patients
completed the Mini-Mental State Examination (MMSE).23 In
addition, sample 1 completed the Dementia Rating Scale.24
Patients with an MMSE score >16 completed a neuropsycho-
logical battery consisting of (1) the multiple-choice version of
the Benton Visual Retention Test,25 the Judgement of Line
Orientation Test26 and the Stroop Word Test.27 These neurop-
sychological tests were selected to identify cognitive deficits
typically occurring in Parkinson’s disease,28 and were as much
as possible independent of motor abilities. The tests were
administered by a neuropsychologist, and scored according to
conventional procedures outlined in the test manuals. A
detailed description of the test battery is made elsewhere.5
Sample 2 completed the Cambridge Cognitive Examination, the
cognitive section of the Cambridge Mental Disorders of the
Elderly Examination.29 To qualify for a diagnosis of dementia,
the interview and the cognitive rating scales had to be
compatible with a diagnosis of dementia. The final diagnosis
was made by one of the authors (DA) on the basis of all
available information except the MRI scan. Further details of
the clinical assessment of sample 1 can be found in Tandberg et
al 30 and Aarsland et al.31 Psychiatric symptoms were assessed
using the Neuropsychiatric Inventory32 in all patients with
Parkinson’s disease with cognitive impairment to detect
cognitive impairment secondary to psychiatric syndromes such
as depression.
Table 1 Characteristics of participants
PDD PDND Controls p Value
Participants 16 20 20 NA
Female/male 6/10 11/9 10/10 0.56
Mean age 73.5 (6.5) 72.5 (8.5) 73.3 (6.3) 0.9
Mean MMSE score 19.4 (4.6) 28.2 (2.1) 29.6 (0.7) ,0.001*
Mean education (years) 10.2 (3.6) 11.0 (3.6) 12.1 (4.3) 0.31
Mean H&Y stage 3.0 (0.6) 2.4 (0.6) NA 0.008
Mean duration of PD (years) 12.3 (7.5) 12.0 (6.3) NA 0.38
H&Y stage, Hoehn & Yahr stage; MMSE, Mini Mental State Examination; NA, non-applicable; PD, Parkinson’s disease;
PDD, Parkinson’s disease with dementia; PDND, Parkinson’s disease without dementia.
*Significantly lower mean value in PDD compared with PDND and controls.
Higher H&Y stage in PDD compared with PDND.
Standard deviation is given in parentheses.
Table 2 Characteristics of patients with Parkinson’s disease without dementia
MCI No MCI p Value
Participants 8 12 NA
Female/male 5/3 6/6 0.47*
Mean age (years) 77.4 (7.4) 69 (8) 0.057
Mean MMSE score 25.9 (2.9) 29.4 (0.5) 0.007
Mean education (years) 8.4 (1.5) 12.5 (3.6) 0.013
Mean H&Y stage 2.6 (0.8) 2.3 (0.4) 0.52
Mean duration of PD (years) 10.8 (3.7) 14.1 (7.1) 0.52
H&Y stage, Hoehn and Yahr stage; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; NA, non-
applicable; PD, Parkinson’s disease.
*Fishers exact test.
Standard deviation is given in parentheses.
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Mild cognitive impairment
MCI was defined according to the criteria proposed by Petersen
et al33: impaired performance (ie, >1K standard deviation (SD)
below the mean of a control group matched with the PDND
group for age, sex and education) on one, two or all three
neuropsychological tests. In addition, information regarding
memory problems or other subjective cognitive deficits was
gathered by means of the care giver-based dementia interview
and the mentation item from the mental subscale of Unified
Parkinson Disease Rating Scale.34 MCI was diagnosed if
cognitive impairment on testing and from the interview was
not severe enough to affect activities of daily living, and thus
the criteria for dementia were not met. For a more detailed
description of the MCI diagnosis, see Janvin et al.7
Control group
Healthy elderly controls were recruited from the local
Parkinson interest group, elderly people from local clubs for
retired people and from relatives of patients with Parkinson’s
disease or other neuropsychiatric disorders. The controls had no
active neurological or psychiatric disorder. They had no
cognitive deficits, and were not taking drugs that could affect
their cognition. A minimum MMSE score of 28 was required.
Written consent was obtained from all patients and controls,
and the study was approved by Regional Committee for Medical
Research Ethics, University of Bergen, Bergen, Norway.
Exclusion criteria
Patients with other known brain disorders apart from
Parkinson’s disease, Parkinsonism due to antipsychotic or
other drugs, or a history of schizophrenia or bipolar disorder
were not included. To avoid inclusion of patients with dementia
with Lewy bodies, patients with clinical signs of cognitive
impairment during the first year after onset of Parkinson’s
disease were excluded according to the International Consensus
Criteria.35 We checked the standard sequences of the MRI scans
(T1, dual fast field echo (FFE) and T2 flair) before the inclusion
of a patient or control, and those who had structural
abnormalities in the brain affecting the grey matter were
excluded from VBM analysis. Patients with marked tremor,
which interferes with the imaging session and produces
movement artefacts, were also excluded.
Magnetic resonance imaging
The subjects were scanned at the Department of Radiology,
Stavanger University Hospital, in the period from December
2001 to June 2005, in a 1.5-T Phillips Gyroscan NT intra release
8.1 (Philips Medical Systems, Best, The Netherlands). The
software of the machine was upgraded in the autumn of 2003,
to Release 10. This has not affected the quality of the images,
which has been stable throughout the study. We performed a
structural MRI series with a T1-weighted three-dimensional
fast, spoiled gradient recalled echo (TR 12.4 ms, TE 4.2 ms, TI
650 ms, matrix 2566192, slice thickness 1.6 mm).
Image analysis
Standard sequences (T1, dual FFE, T2 flair) were examined to
visualise focal lesions of grey matter that might lead to
exclusion of patients from the study. These sequences were
not used for statistical image analysis in this study, but results
on visual rating of white matter hyperintensities can be found
in Beyer et al.36
VBM preprocessing
The optimised VBM protocol of Good et al37 was applied for the
preprocessing of the images, including creating a study-specific
T1 template image (based on all the patients and controls in our
study) and a study-specific grey matter template/prior prob-
ability map. The preprocessing steps have already been
described in detail by others.12 37 The first preprocessing step
includes the creation of the customised templates. T1 images of
each patient were normalised to the T1 template of statistical
parametric mapping (SPM)2 using an affine only cut-off. After
normalising, images were averaged and then smoothed with an
8 mm kernel, creating the T1 template. Normalising the
original images to the customised T1 template using a 25 mm
cut-off created the customised grey matter template. The
normalised images were then segmented and smoothed with
an 8 mm kernel. The smoothed grey matter images were then
averaged, creating the study-specific grey matter template.
These templates were used in the optimised VBM protocol in
the following manner: the original images were segmented and
the grey matter images were normalised to the customised grey
matter template. The resulting normalisation parameters were
used to normalise the original T1 images before the final
segmentation. Segmented images were then smoothed with a
12 mm kernel. The resulting smoothed images were used in the
statistical analysis.
Statistical analyses
The smoothed images from the preprocessing steps were
analysed using SPM2 (Wellcome Department of Cognitive
Neurology, London, UK (http://www.fil.ion.ucl.ac.uk/spm)).
Smoothed images that are used to show regional changes in
grey matter, above that occurring globally, are referred to as
unmodulated images.
The following VBM analyses of grey matter were performed:
for unmodulated images, we statistically assessed differences in
grey matter between groups using one-way analysis of variance
(ANOVA). We also performed analyses where age, sex and
duration of Parkinson’s disease were included as covariates in
analysis of covariance (ANCOVA). For all analyses, the whole
brain was analysed. As we had a prior hypothesis about the
localisation of change, significance levels for t statistics were set
at p,0.001 uncorrected. All the results are presented at the
voxel level.38 In addition, we performed a small volume
correction (SVC) using the WFU PickAtlas software V.2,39 40
and corrected for multiple comparisons using p family-wise
error (FWE) ,0.05. The SVC reduces the number of voxels
entering the statistical computation by defining a region of
interest. The correction for multiple comparisons is based on
the number of voxels in the region of interest.
The coordinates obtained for the peak voxels—that is, the
anatomical location with maximal grey matter loss in each
significant cluster—were transferred into Talairach space using
Matthew Brett’s mni2tal routine (http://www.mrc-cbu.cam.a-
c.uk/imaging/index.html).
The anatomical locations of the peak voxels were then found
using The Talairach Daemon Client.41 The results given by the
Talairach Daemon were verified from the Co-planar stereotaxic
atlas of the human brain.42 Data were analysed on a personal
computer using Windows XP Professional V.5.1 and Matlab
6.5.2 and SPM2 (http://www.fil.ion.ucl.ac.uk/spm).
Group statistics were analysed using SPSS for Windows
V.12.0.1. Differences between groups on continuous variables
with normal distribution were assessed using one-way ANOVA
with retrospective Scheffe’s test to determine group differences.
For the non-parametric data a Kruskal–Wallis test was used,
followed by a retrospective Mann–Whitney U test, or a x2 test,
when appropriate, using p,0.05 as significant.
RESULTS
A total of 56 participants were included: PDD (sample 1, n = 3;
sample 2, n = 13), PDND (sample 1, n = 14; sample 2, n = 6)
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and normal controls (n = 20). Table 1 presents the demographic
and clinical characteristics. We found no significant differences
in age, education, duration of illness or sex between the three
groups. As expected, patients with PDD had a lower MMSE
score and a higher Hoehn and Yahr stage than those with
PDND. The mean duration of dementia in the PDD group was
1.7 (SD 0.8) years. In the PDND group, 12 subjects had normal
cognitive status and 8 had MCI (5 were impaired on 1 test, 2 on
2 and 1 on all 3 tests; table 2). The patients with MCI had a
lower mean duration of education (p = 0.013; table 2) and a
non-significant trend towards higher age (p = 0.057). As
expected, patients with MCI had a lower MMSE (p = 0.007)
compared with those with a normal cognitive status (table 2).
Eight patients were recruited for MRI, but not included in the
study. Two patients became agitated during the scanning, two
patients had movement artefacts, three had clinically unrecog-
nised structural lesions, such as a cortical infarction or a post-
traumatic lesion, and one patient could not be scanned in the
correct head position. One control was excluded because of
claustrophobia. Mean (SD) time between clinical testing and
MRI scanning was 69 (19.8) days for sample 1 and 40
(23.1) days for sample 2.
MRI changes in patients with PDND and PDD
Patients with PDD versus controls
Patients with PDD had reductions in grey matter concentration
in the limbic lobes (amygdala) and both temporal lobes,
compared with the controls. On the left side, there was also
reduced grey matter density in the frontal lobe, limbic lobe
(cingulate and hippocampus) and brain stem red nucleus. On
the right side, there was reduced grey matter density in the
middle occipital gyrus (see supplemental table A at http://
jnnp.bmjjournals.com/supplemental). When we included age,
sex and Parkinson’s disease duration as covariates in ANCOVA,
the results were unchanged. We found no areas where controls
had more grey matter atrophy than patients with PDD. Using
an SVC and correcting for multiple comparisons, the bilateral
reduction in grey matter in the middle temporal gyrus and
amygdala, and also in the left brain stem red nucleus, was
significant at p FWE ,0.05.
Patients with PDD compared with those with PDND
In patients with PDD, there were areas of marked grey matter
reduction in the frontal lobes, limbic, parietal and temporal
lobes bilaterally. On the right side, there was also reduced grey
matter density in the pulvinar of the thalamus (see supple-
mentary table B at http://jnnp.bmjjournals.com/supplemental).
The areas surviving SVC with correction for multiple compar-
isons using FWE are marked with an asterisk in the table. The
results did not change when age, sex and duration of
Parkinson’s disease were included as covariates in ANCOVA.
There were no areas where patients with PDND had more
grey matter atrophy than patients with PDD.
Patients with PDND compared with normal controls
Patients with PDND had a cluster of reduced grey matter in the
right superior temporal gyrus compared with normal controls.
The result was unchanged when covariates were included, but
was not significant after SVC and correction for multiple
comparisons. Normal controls did not have any areas of more
grey matter atrophy than PDND.
Group comparison of patients with PDND with and
without MCI
Patients with Parkinson’s disease with MCI had reduced
cortical grey matter density compared with those with
cognitively intact Parkinson’s disease in the left middle frontal
gyrus, precentral gyrus, left superior temporal lobe and right
inferior temporal lobe (fig 1, table 3). The findings were not
significant after SVC and correction for multiple comparisons.
When we analysed with age and sex as covariates in ANCOVA,
the changes were no longer present, but when analysed with
duration of Parkinson’s disease as covariate the same changes
in grey matter were found as in the ANOVA. Patients with
Parkinson’s disease without MCI did not have any areas of
more grey matter atrophy than patients with Parkinson’s
disease with MCI.
DISCUSSION
We studied grey matter changes in patients with Parkinson’s
disease with MCI and dementia using structural MRI and VBM.
L R L R RL
A B C
Figure 1 Areas of reduced grey matter in the analysis of unmodulated
images of patients with Parkinson’s disease with mild cognitive impairment
(MCI) compared with those who had no cognitive impairment. The figure
shows areas of regional changes in grey matter, above that occurring
globally, in patients with Parkinson’s disease without dementia and MCI.
Significant changes are found in the (A) left superior temporal gyrus, (B) left
frontal lobe (precentral gyrus) and (C) right temporal lobe (inferior
temporal gyrus) and left temporal lobe (superior temporal gyrus) at
p,0.001 uncorrected. L, left side, R, right side.
Table 3 Anatomical location of areas of reduced grey matter in patients with Parkinson’s
disease with mild cognitive impairment compared with no cognitive impairment
Cluster size
Voxel
level Anatomical location x y z T score
420 L Superior temporal 230 21 228 5.31
103 L Precentral gyrus 258 25 11 4.75
75 R Inferior temporal 55 220 221 4.49
79 L Superior temporal 262 222 3 4.27
107 L Precentral gyrus 242 25 56 4.08
L Middle frontal 239 3 58 3.74
L, left; R, right.
The coordinates x, y and z refer to the anatomical location, indicating standard stereotactic space as defined by
Talairach and Tournoux.42 Only clusters .200 mm3 are included. In this table, all reported voxels are p uncorrected
,0.001.
MRI study of patients with Parkinson’s disease 257
www.jnnp.com
The main finding was the widespread reduced density of
cortical grey matter in patients with PDD compared with
controls and patients with PDND. Frontal, temporal and limbic
lobes, including the medial temporal cortex, were affected in
patients with PDD, in accordance with our hypothesis. They
also had reduced grey matter concentration in the parietal
cortices and the right thalamus when compared with patients
with PDND. We found grey matter reduction in the hippocam-
pus (right side) and amygdala (bilaterally) in the PDD group.
This confirms the results from previous studies with different
methods of MRI analysis.9 12
Our results are similar to but not identical with, those
reported in a previous study using VBM.12 In that study,
patients with PDD showed bilateral frontal, temporal and
occipital grey matter volume loss relative to controls, whereas
the changes between PDND and PDD groups were confined to
the occipital lobes. There are several possible explanations for
these differences. The patients with PDD in the two studies
were comparable with regard to age and overall severity of
dementia as measured with the MMSE, but the PDD group in
the previous study had a markedly shorter disease duration
compared with our cohort. Thus, that cohort had a later age at
onset of Parkinson’s disease, and an earlier and more rapid
cognitive decline than our cohort. Dementia early in the course
of Parkinson’s disease has often been shown to represent other
brain disorders,43 and preliminary data indicate differential
changes in the brain underpinning dementia occurring within
the first 10 years after the onset of Parkinson’s disease
compared with after .10 years.44 Different underlying changes
in the brain related to differences in the time to develop
dementia may therefore explain the MRI findings in these two
studies. Another possible explanation is the higher statistical
power in the previous study due to a larger sample size (n = 83)
than in our study (n = 56). This hypothesis is supported by a
recent report finding less widespread neocortical atrophy with
an even smaller sample size (n = 42).13 The small sample size of
the groups studied limits the possibility of generalising from
these results.
Another potential explanation for the contrasting results
among these studies may be the differential selection process of
patients; about half of our sample was recruited from a
community-based study and the rest from patients referred to
outpatient clinics, compared with samples based on only
referrals to specialist clinics in the other studies. In line with
this, the patients with Parkinson’s disease in the Spanish
study45 were younger than the patients in our study. There were
also differences in sex distribution, although sex-specific
differences in MRI in Parkinson’s disease have not been
shown. Finally, information of the detailed cognitive profile
in the two studies was not available. Despite similar overall
dementia severity, differences in the cognitive profile—for
example, relative severity of frontal, visuospatial and memory
type cognitive disturbances—were observed in groups of
patients with Parkinson’s disease and PDD,4 46 which may be
related to differences in the severity and distribution of cortical
atrophy.
As motor disease severity in Parkinson’s disease was greater
in the PDD group than the PDND group, the differences
observed in cortical atrophy may be merely associated with the
different motor disease stage. When controlling for Hoehn &
Yahr stage in the analysis of patients with PDND versus those
with PDD, we still found the same areas of atrophy. This
indicates that our findings cannot be explained entirely by the
increased motor disease severity in PDD.
A novel finding was the cortical grey matter reduction in
patients with PDND with MCI compared with patients with
Parkinson’s disease with normal cognition.
Several studies have shown that cognitive impairment, in
particular executive and attentional dysfunction, is common
even in patients with PDND.4 46 In contrast with a previous
study,12 which reported widespread cortical changes also in
patients with PDND, we found only minimal differences in
patients with PDND compared with controls. However, when
the patients with PDND were classified into groups with or
without MCI, we found areas of grey matter atrophy in the MCI
group compared with the cognitively intact group. These results
were in accordance with our hypothesis.
In this study, the grey matter atrophy in Parkinson’s disease
with MCI was found in the ANOVA, and in the ANCOVA with
Parkinson’s disease duration as covariate, whereas the differ-
ences were not present when age was entered as a covariate.
This could be due to the low power with 8 v 12 patients in the
compared groups, and even lower degrees of freedom with a
covariate in the analysis, or that atrophy is due to the age
difference between groups. However, as changes were found in
some of the same areas as in the PDD group, but less
widespread, this may indicate that MCI in Parkinson’s disease
is associated with cortical atrophy and may represent early
dementia. Similar results from other studies using VBM and
volumetry in subjects without Parkinson’s disease with MCI
support our view. Atrophy in areas that are involved early in
Alzheimer dementia, such as the hippocampus and temporal
neocortex,47 48 and in the hippocampal region and cingulate
gyri49 has been reported.
The main limitations of this study is the small sample size,
particularly of patients with Parkinson’s disease with MCI, the
possibility of selection bias, as a proportion of the patients with
Parkinson’s disease were referrals to outpatient hospital clinics,
and the lack of pathological confirmation of the clinical
diagnosis of Parkinson’s disease in most cases.
Future imaging studies and clinicopathological studies with
adequate sample size are needed to further explore the
relationship between specific cognitive deficits and the under-
lying brain correlates in Parkinson’s disease, and to see whether
MRI can contribute in the early diagnosis of dementia in
Parkinson’s disease.
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Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy 
bodies 
Mona K. Beyer, MD; Jan P. Larsen, MD, PhD; Dag Aarsland, MD, PhD 
 
ABSTRACT 
Background: The nosologic relationship between dementia with Lewy bodies (DLB) and 
Parkinson disease with dementia (PDD) is continuously being debated. We conducted a study 
using voxelbased morphometry (VBM) to explore the pattern of cortical atrophy in DLB and 
PDD. 
Methods: Seventy-four patients and healthy elderly were imaged (healthy elderly n= 20, PDD 
n =15, DLB n = 18, and Alzheimer dementia [AD] n = 21).Three dimensional T1-weighted 
MRI were acquired, and images analyzed using VBM. The following diagnostic criteria were 
used: criteria proposed by the third report of the DLB Consortium for DLB, the National 
Institute of Neurologica and Communicative Disorders and Stroke and the Alzheimer’s 
Disease and Related Diseases Association criteria for AD, and Diagnostic and Statistical 
Manual of Mental Disorders, fourth edition criteria for dementia in PDD. 
Results: Overall dementia severity was similar in the dementia groups. We found more 
pronounced cortical atrophy in DLB than in PDD in the temporal, parietal, and occipital 
lobes. Patients with AD had reduced gray matter concentrations in the temporal lobes 
bilaterally, including the amygdala, compared to PDD. Compared to DLB, the AD group had 
temporal and frontal lobe atrophy. 
Conclusion: We found that despite a similar severity of dementia, patients with dementia with 
Lewy bodies (DLB) had more cortical atrophy than patients with Parkinson disease with 
dementia (PDD), indicating different brain substrates underlying dementia in the two 
syndromes. Together with previous studies reporting subtle clinical and neurobiologic 
differences between DLB and PDD, our findings support the hypothesis that PDD and DLB 
are not identical entities, but rather represent two subtypes of a spectrum of Lewy body 
disease.  
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Abstract 
Background 
There is considerable heterogeneity within patients with Parkinson’s disease (PD) regarding time from 
onset of PD to dementia. Age, mild cognitive impairment and severity of parkinsonism are the main 
factors influencing the time from onset of disease to dementia in PD. We compared grey matter 
atrophy using magnetic resonance images (MRI) of patients with PD who developed dementia early 
and late in the disease course. 
Methods 
Fifteen patients diagnosed with PD who developed dementia before (n=9) or after (n=6) 8 years 
duration of PD were included. They were diagnosed according to established criteria for PD and 
dementia, and rated using standardized scales assessing motor, cognitive and psychiatric symptoms. 
We then compared MRI of the groups with Voxel Based Morphometry (VBM). 
Results 
Despite similar age and severity of dementia and parkinsonism, the group with early dementia had 
more atrophy than the group with late dementia in some areas (the striatum (right caudate, left 
putamen), in the left precentral gyrus, left middle temporal gyrus and in the right red nucleus). The late 
dementia group had symmetrical reduction in grey matter in the insula bilaterally compared to the early 
dementia group. 
Conclusion 
Our results indicate that the early development of dementia in PD is associated with more severe 
degeneration of cortical and sub-cortical structures.  
 
Key words: Parkinson’s disease, dementia, MRI, atrophy. 
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Introduction 
 
Recent longitudinal studies indicate that the majority (up to 80%) of older patients with Parkinson’s 
disease (PD) also eventually develop dementia.[1] Parkinson’s Disease Dementia (PDD) is a 
distressing condition characterized by parkinsonism, executive, visuo-spatial and attentional 
impairment.[2, 3]  Visual hallucinations and REM sleep behavior disorder (RBD) are also common in 
PDD,[4, 5] [6] resulting in major difficulties for clinical management.  
 
Studies of the neuropathology and neurochemistry of PD have shown that Lewy bodies are mainly 
located in the substantia nigra and other brainstem nuclei,[7] with a resulting extensive loss of striatal 
dopaminergic neurons[8] and neocortical cholinergic innervation[9, 10] which are greater in patients 
with concurrent cognitive impairment.  The consensus from neuropathological studies focusing upon 
PDD is that diffuse cortical Lewy bodies are the main substrate of dementia in these patients.[11, 12] 
Limbic Lewy bodies were thought to be associated with dementia in PD,[13] but a later study has 
shown an association between limbic lewy bodies and visual hallucinations and no relation to severity 
or duration of dementia.[14]  
There is considerable heterogeneity within PD patients[15] including time from onset of PD to 
dementia. The mean duration of PD from onset to development of dementia is 10-12 years, but some 
develop dementia after 6-7 years or less, while others develop dementia after 15 years or more.[16] 
Age, mild cognitive impairment and severe parkinsonism are the main factors influencing the time from 
onset of disease to dementia in PD.[17, 18] Visual hallucinations and male gender have also been 
identified as clinical predictors of PDD.[19] In particular, motor symptoms other than tremor, such as 
postural and gait disturbances, have been found to be associated with a shorter time to dementia,[20] 
indicating an association between pathologies underlying cognition and certain motor symptoms. 
 
A recent neuropathological study reported different brain changes underlying dementia occurring early 
(ie before 9.5 years after onset of PD) compared to later in the course of the disease.[21] Imaging 
studies have found more cortical atrophy in PDD versus PD.[22, 23] However, to our knowledge, no 
study has explored whether pattern and degree of atrophy differs in PD patients with early and late 
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occurring dementia. Such knowledge would aid in the understanding of the etiology of dementia in PD, 
the clinical heterogeneity of PD, and to the relationship of PDD and dementia with Lewy bodies (DLB).  
 
We compared brain MRI from two groups of PDD where one group developed dementia early in the 
course ie. before  or including 8 years of PD duration, while the second group developed dementia 
after more  than 8 years of PD duration. Our hypothesis was that patients with dementia early in the 
disease course, have more atrophy than patients with dementia occurring late.  
 
Methods 
Case-finding and diagnostic procedures 
Fifteen patients with PDD referred to the Department of Neurology, and the Department of Geriatric 
Psychiatry at Stavanger University Hospital, Norway comprised the study group.  
Diagnosis of PD and dementia 
A diagnosis of PD was made by a neurologist specialized in movement disorders according to explicit 
criteria.[24] A minimum requirement for a diagnosis of PD was two or more of the four cardinal signs 
for PD (i.e. resting tremor, bradykinesia, rigidity, and postural instability), and the response to a 
dopaminergic agent should be at least moderate.  
Diagnosis of PDD was made in a patient fulfilling PD criteria who also fulfilled criteria for dementia 
based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for dementia due 
to PD[25]. Patients were examined by a psychiatrist and a research nurse both trained in 
neuropsychiatry. A clinical medical examination and routine laboratory tests were also performed. To 
qualify for a diagnosis of dementia, the interview and the cognitive rating scales had to be compatible 
with a diagnosis of dementia. Patients with a notable cognitive impairment before or within 1 year after 
onset of PD were not included, to exclude patients with DLB.[26]. Staging of PD was carried out 
according to the UPDRS motor sub-scale[27] and Hoehn & Yahr scale.[28] All patients performed Mini 
mental state examination (MMSE), a brief cognitive screening test[29]. In addition, patients completed 
the Dementia Rating Scale[30] or the CAMCOG, the cognitive battery of the Cambridge Mental 
Disorders of the Elderly Examination (CAMDEX).[31] 
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Age at diagnosis of PD and time of onset of clinically significant cognitive impairment indicating 
dementia was based on a detailed interview of the patient or caregiver. In addition case-notes from the 
departments were carefully studied. This assessment was done independent of and blind to the 
imaging results. The time from PD diagnosis to onset of dementia varied from 3 to 28 years, and the 
median was 8 years. Patients were classified as early dementia if dementia occurred 8 years or less 
before PD diagnosis (n=9), and late dementia if dementia occurred later than 8 years after PD 
diagnosis (n=6).  
Magnetic Resonance Imaging 
Patients were scanned at the Department of Radiology, Stavanger University Hospital in the period 
from December 2001 to June 2005, in a 1.5 T Phillips Gyroscan NT intera, Release 8.1 MRI machine ( 
Philips Medical Systems, Best, The Netherlands) A software upgrade of the machine was done in the 
fall  2003, to release 10. The quality of the images has been stable throughout the study. We 
performed a structural MRI series with a T1- weighted three dimensional (3D) fast spoiled gradient 
recalled echo (FSPGR), (TR 12.4 ms, TE 4.2 ms, TI 650 ms, matrix 256 x 192, slice thickness 
1.6 mm).  
Image analysis 
The optimised VBM protocol of Good et al [32] was applied for the preprocessing of the images. The 
preprocessing steps are already described in a previous paper.[23] The resulting smoothed images 
were used in the statistical analysis. 
Statistical analysis 
Smoothed images from the pre-processing steps were analyzed using statistical parametric mapping 
(SPM2) (Wellcome Department of Cognitive Neurology, London, UK (http://www.fil.ion.ucl.ac.uk/spm). 
Data were analysed on a PC using windows XP professional, version 5.1 and Matlab 6.5.2 
(Mathworks, Natick, MA).  
The following voxel-based analyses of grey matter were performed: 
Differences in grey matter between groups were assessed statistically using a two sample t-test, 
analysing the whole brain. Significance levels for t - statistics were set at p<0.001 uncorrected for 
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multiple comparisons. All results are presented at the voxel level.[33] Smoothed, modulated images 
were also analysed. The co-ordinates obtained for the peak voxels, ie the anatomic location with 
maximal grey matter loss within each significant cluster, were transferred into Talairach space using 
Matthew Brett’s mni2tal routine (http://imaging.mrc-cbu.cam.ac.uk/imaging/MniTalairach). 
The anatomic locations of the peak voxels were  found using The Talairach Daemon Client[34]. The 
results given by the Talairach daemon were verified by the Co-planar Stereotaxic Atlas of the Human 
Brain[35]. When discrepancies in the location of peak voxels were found, the manually detected  
anatomic locations were reported.   
Group statistics were done using the SPSS for windows, version 13.0 (SPSS for Windows, Release 
13.0 (1 Sep 2004) SPSS Inc). Differences between groups were assessed using Mann Whitney U test, 
or a chi-square test was used when appropriate, using p< 0.05 as statistically significant. 
 
Results 
There were no significant differences between the early and late dementia groups regarding age, 
education, severity or duration of dementia, severity of parkinsonism or drug treatment, although the 
late dementia group had a numerical lower MMSE score (Table 1). There were more females and the 
age at onset was younger in the late dementia group than the early dementia group (Table 1).  
The early dementia group had areas of more atrophy than the group with late  dementia. The areas of 
reductions in gray matter volume were bilaterally in the medial frontal gyrus, and in the right 
precuneus, and on the left side in the inferior parietal lobule, superior frontal gyrus and middle 
temporal gyrus. In the group with long disease duration prior to dementia we found symmetrical gray 
matter volume reduction in the inferior frontal gyrus bilaterally.  
In the unmodulated images, the group with early dementia had more atrophy than the group with late  
dementia in the striatum (right caudate, left putamen), in the left precentral gyrus, left middle temporal 
gyrus and in the right red nucleus. (Table 2, Figure 1)The late dementia group had symmetrical 
reduction in gray matter in the insula bilaterally compared to the early dementia group. (Table 2, 
Figure 1) 
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Discussion 
The main finding of this study is that PD patients who developed dementia early in the disease course 
had areas of more atrophy than PD patients who developed dementia late in course, consistent with 
our hypothesis. These differences could not be explained by differences in clinical features such as 
severity of dementia or parkinsonism or age. The findings are in line with a recent neuropathology 
study who found more morphological brain pathology (plaques and α-synuclein ) in the group with 
shorter duration of PD prior to dementia.[21] In addition we found a symmetrical reduction in gray 
matter in the insula bilaterally in the long duration PDD group. 
Structural imaging studies have previously shown atrophy of similar areas as those found in the 
current study; the right caudate nucleus,[22] the left middle temporal, left precentral gyrus[23] and 
putamen[36]  in PDD patients, although conflicting results have been reported.[37] The novel finding in 
this study is that this atrophy is more pronounced in some areas in patients who develop dementia 
early in the disease.  
We found symmetrical gray matter reductions in the insula in the group with 8 years or more duration 
of PD prior to dementia. This confirms the results of a previous VBM study of patients with PDD,[22] 
and a longitudinal VBM study of PDD patients where bilateral insula reductions were found.[38] 
 
The structures with more atrophy in those with early dementia in our study have previously been found 
to be related to cognitive and neuropsychiatric features. The basal ganglia are not only involved in 
motor function, but are also engaged in cognitive functions.[39, 40] A PET study of PDD patients 
showed decreased uptake of 18F-dopa in the caudate and mesolimbic structures compared to non 
demented PD patients, suggesting that dementia in PDD is related to reduced function in these 
areas.[41]  
There is a remarkable inter-individual variation in the course of PD, both regarding motor[42] and 
cognitive decline[16] and age at onset of PD.[15] The relationship of age and age at onset with clinical 
course is complex. Age at disease onset was the main predictor of motor decline, indicating a slower 
and more restricted pathologic disease process in patients with young-onset PD.[43] In contrast, age 
but not age at onset, was associated with time to dementia after adjustment for the overall effect of 
age on the risk of dementia in non-PD subjects.[16] In our study the patients in the early dementia 
group were older at PD debut than the late dementia patients. There were also numerical differences 
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in age at scanning, but this was not significant, and no association between age and rates of atrophy 
in PD has been found.[44] We did not attempt to disentangle the relationship between age and age at 
onset with time to dementia.  
 
Neuropathological heterogeneity in PD has been reported, although the pathological variability 
underlying the clinical heterogeneity is not known in detail.[15] Together with a recent 
neuropathological study [21], our findings suggest that a differential degeneration of cortical and 
subcortical structures is underpinning the variation in time to develop dementia. Braak hypothesized a 
systematic progression of Lewy pathology emerging in the brain stem and subsequently involving 
basal forebrain and finally neocortex.[45] Our findings indicate that although the overall pattern may be 
valid, there are clinically significant variations in the regional progression of the pathology, with more 
rapidly progressing atrophy in some patients. In contrast, neurochemical changes may play a larger 
role in the group with late onset dementia, consistent with the findings in the autopsy study [21].  The 
factors regulating this differential disease progression, in part related to age, needs to be further 
explored in future studies. 
 
Our study has methodological limitations that need to be addressed. The study groups are small, and 
differed on some demographic and clinical variables. Thus, our findings should be interpreted with 
caution, and larger groups are needed to confirm our results. The diagnosis of PD was clinical, and 
thus misdiagnosis may occur. However, neuropathological verification of PD diagnoses from our 
hospital have been demonstrated[12]. Finally, this was a cross-sectional study, and the time from 
onset of PD to dementia was based on a clinical interview of patient and caregiver, and thus recall 
bias cannot be ruled out. It is however unlikely that this introduced a systematic bias that would affect 
the results. 
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Table 1 
Clinical and demographic characteristics of the groups according to timing of dementia and 
parkinsonism 
 
 PD ≤ 8 years PD > 8 years P (Mann Whitney) 
N 9 6 - 
Gender male/female 8/1 2/4 0.047* 
Age 74 (69-84)  69.5 (62-82) 0.46 
Education (years)  9 (7-17) 7.5 (7-17) 0.69 
MMSE  21 (13-25)  18 (10-24) 0.39 
UPDRS  40 (29-45) 39.5 (18-60) 0.714 
H&Y 3.0(2-4)  3.0 (2.5-4) 0.514 
Dementia duration (years)  2 (1-3)  2 (1-5) 0.753 
Duration of PD (years) 6(5-10)  19.5 (12-30) 0.001 
Age of PD debut  67(59-78)  53 (32-67) 0.015 
L-dopa dose (mg)  600 (400-800)  925 (500-1200) 0.18 
 
Median (range) 
Fishers exact test 
Duration of PD = duration from PD diagnosis, not start of symptoms
 15
Table 2 
Brain areas showing significant differences between groups 
 
Areas with reduced gray matter in patients with ≤ 8 years PD duration 
Talairach Coordinate  
x y z Structure Cluster size Z score 
12 10 -5 R caudate nucleus 144 3.97 
-12 10 -10 L putamen 104 3.75 
-39 -16 37 L precentral gyrus 60 3.47 
-55 -40 -3 L middle temporal gyrus 104 3.44 
3 -21 -4 R brainstem, red nucleus 101 3.34 
Areas with reduced gray matter in patients with > 8 years PD duration 
x y z Structure Cluster size Z score 
38 15 15 R insula  189 4.49 
-33 21 13 L insula  194 4.01 
 
All peak voxels are p< 0.001 uncorrected. Only clusters larger than 200 mm³ /60 voxels are shown. 
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Figure 1 
 
A) Areas of reduced gray matter in patients with ≤ 8 years of PD duration prior to dementia 
B) Areas of reduced gra matter in patients with >8 years of PD prior to dementia 
development 
 
 
 
 
 
 
Results shown on glassbrain, where areas of atrophy are shown as gray and black clusters (p<0.001 
uncorrected). 
 
 
 
B
